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 L'inflammation et le stress oxydatif (OxS) participent à la pathogenèse de la colite ulcéreuse 
(CU). Nos résultats récents montrent que les polyphénols de la pelure de pomme (DAPP) 
jouent un rôle clé dans la prévention de la maladie.  
Objectifs:  
Évaluer les effets préventifs et curatifs du DAPP sur la CU et démontrer leur impact sur la 
dysfonction mitochondriale.  
Méthode:  
Une induction de l’inflammation intestinale a été effectuée chez des souris par administration 
du dextran sulfate sodium (DSS). Des doses de DAPP (200 et 400 mg/kg/j) ont été 
administrées par gavage pendant 10 jours afin d’évaluer les effets préventifs et curatifs, 
respectivement, sur l’Inflammation et le OxS  au niveau intestinal ainsi que sur les fonctions 
mitochondriales.   
Résultats:  
Le DSS a provoqué une perte de poids, un raccourcissement du côlon, une augmentation du 
stress oxydant, niveaux de malondialdéhyde  et une inflammation documentée par l’infiltration 
des cellules inflammatoires, la myéloperoxydase et les cytokines inflammatoires. D’autre part, 
le DSS a induit des désordres au niveau de la biogenèse (PGC1α) et des fonctions de la 
mitochondrie : diminution de l’ATP, altération des enzymes antioxydantes (SOD2 et GPX1), 
augmentation de l’apoptose (Bcl 2, Bax  et Cytochrome C), et des défauts de l’intégrité de 
l’ADN (baisse d’OGG1). Cependant, le DAPP a amélioré significativement l’inflammation et 
le stress oxydant de l’intestin tout en corrigeant les aberrations mitochondriales.  
Conclusions:  
Les polyphénols ont la capacité d’agir sur le stress oxydant et le profil inflammatoire de 
l’intestin ainsi que sur le dysfonctionnement mitochondrial. Ils pourraient donc intervenir 
efficacement dans la CU. 
 






We have recently shown that dysregulation of redox-sensitive signaling pathways and 
oxidative damage to biological structures are major contributors to experimental ulcerative 
colitis. We also demonstrated the powerful anti-oxidant and anti-inflammatory actions of 
dietary apple peel polyphenols (DAPP) in the intestine.  
Objectives: 
 As mitochondria are major sources and target of free radicals, as well as exhibit various 
important cellular functions, we evaluated their roles in intestinal colitis and their responses to 
DAPP.  
Methods: 
Induction of intestinal inflammation in C57BL6 mice was performed by administration of 3% 
dextran sulfate sodium (DSS). Two different doses of DAPP (200 and 400 mg/kg/day) were 
administered by gavage for 10 days (before and during DSS administration) to examine the 
preventive and curative effects, respectively, on inflammation and oxidative stress (OxS) in 
the intestine, and on mitochondrial functions.  
Results: 
DSS caused a significant weight loss, shortening of the colon, increased OxS (noted by lipid 
peroxidation), and raised inflammation (verified by infiltration of inflammatory cells, up-
regulation of MPO, and elevated TNF-α and COX2 protein expression). Furthermore, DSS 
induced perturbations in mitochondrial biogenesis, as reflected by alterations of the 
transcription factor PGC1α and mitochondrial function characterized by diminished 
Adenosine-5'-Triphosphate (ATP) production, lowered antioxidant defense (GPx and SOD2), 
amplified apoptosis (as illustrated by the high expression of Cytochrome C and AIF), and 
defects in DNA integrity (high 8-OHdG). However, DAPP administration improved 
macroscopic parameters (e.g. weight loss, colon shortening) and reduced DSS-induced clinical 
signs. DAPP showed an evident capability of reducing inflammation (as noted by decreased 
 
iv 
TNF-α, iNOS, COX-2 and AP-1) and OxS (as shown by reduced malondialdehyde, hydrogen 
peroxide levels and increased GPx) in DSS mice. Our findings also revealed that DAPP 
partially corrected mitochondrial dysfunction related to redox homeostasis, fatty acid β-
oxidation, ATP synthesis, apoptosis and regulatory mitochondrial transcription factors 
(PGC1α, PPARγ and Nrf-2). 
 
Conclusion: 
 DAPP have the ability to act on intestinal OxS, inflammation and mitochondrial dysfunction, 
thereby alleviating colitis progression via the modulation of cellular energy, OxS, antioxidant 
capacity, apoptosis and mtDNA integrity.  
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1 INTRODUCTION  
1.1 Introduction to Inflammatory Bowel Diseases  
1.1.1 Pathophysiology and Epidemiology of Inflammatory 
Bowel Diseases 
Inflammatory bowel disease (IBD) is one of the common types of intestinal inflammatory 
diseases. It describes a group of disorders that attack the intestine and cause intestinal 
cells to become swollen and inflamed. In other words, IBD is a series of 
immunoinflammatory disorders of the gastrointestinal (GI) tract, which mainly include 
two main disorders: Crohn’s disease (CD) and ulcerative colitis (UC).  Additional rare 
forms of IBD are observed such as collagenous colitis and intractable colitis [1, 2]. 
 







While the two main forms of IBD, UC and CD, are not as common as heart disease or 
cancer, they cause significant morbidity and financial burden on the health care system.  
Studies have reported that the prevalence of IBD in adults in the United States is more 
than 200 cases per 100,000 with the total number of 1 to 1.5 million IBD patients [3, 4]. 
The prevalence of IBD in the past few years in Canada has been 150-250 cases per 
100,000, and hospitalization due to UC and CD has been evaluated at 50.6 and 50.1 cases 
per 100,000, respectively [5, 6]. 
Recently, research has shown that IBD is more prevalent in developed countries. 
Lifestyle related factors such as nutrition, exposure to pollution and chemicals, low 
physical activity, and decreased exposure to sunlight are associated with the increased 
prevalence of IBD [7]. Other studies revealed that the risk of succumbing to recently 
diagnosed severe and long term cases of IBD is increasing. Moreover, risk of colorectal 
cancer (CRC) has recently raised to 20% per year compared to 0.5% reported previously, 
especially in cases of UC [8]. 
IBD is a multifactorial chronic, recurring and inflammatory disease of the GI tract 
commonly presenting clinical symptoms of diarrhea, bloody stools, abdominal pain and 
weight loss, and the development of an inflammatory response [9].  
In animal models of colitis, the same common macroscopic symptoms are monitored. 
This includes body weight loss, fecal bleeding, stool consistency (e.g., diarrhea, liquid), 
shortening of the colon, and change of intestinal microbiota [10, 11]. In addition, 
experimental study by Islam et al. reported the severe histological changes of murine 






augmented thickness of the muscle layer, lymphocyte infiltration, mucosal erosion, loss 
of crypt structure, ulcer formation and also serious intestinal microbiota modifications 
[12].  
Genetics and possible genetic heterogeneity play a fundamental role in IBD but the 
precise nature of the genetic implication is extremely complex, and it is probable that the 
cooperation of certain genes acts as a responsible modulator. Recently, the genetic study 
by Nell et al. has demonstrated the importance of environmental factors and specifically 
the gut microbiota in the occurrence of CD and UC [13].  
 
1.1.2.  CD and UC: Pathology, signs and Symptoms 
Crohn’s and colitis are known to cause major health problems in the human body and are 
characterized by abnormal chronic inflammation and immune-mediated injury to the GI 
tract. Although the main triggers of IBD disorders are not clearly identified, recent 
studies have reported that, generally, the complex relations between genetic determinants 
(e.g. IBD1, IBD2…), unfavourable environmental factors (smoking, diet, stress, drug, 
social status, education), dysregulated immune response and qualitatively and 
quantitatively unusual gut microbiota could be the main determinants in the pathogenesis 







 The common pathogenic factors in IBD. Taken from de Souza Figure 2.
et al. [15]. This image shows that IBD can develop due to the body’s distorted 
and changed immune response, changes in intestinal microbiota, a complicated 
interplay of genetic predisposition and environmental factors. 
 
High levels of oxidative stress (OxS), mitochondrial DNA mutations and dysfunction in 
mitochondrial calcium (Ca2+) pathway can fundamentally cause or affect intestinal 
inflammation directly or indirectly, thereby increasing the risk of IBD as briefly 



















 Risk factors involved in the pathogenesis of UC and CD.  Figure 3.
CD and UC have been studied in parallel, as their common symptoms, structural damage 
and treatments are very similar. However, it is known that they are characterized by two 
separate pathophysiological patherns. 
In CD, all parts of the GI tract, from the mouth to anus could be affected, but the disease 
generally affects the distal part of the small intestine or ileum.  On the other hand, UC 
only causes colonic inflammation and affects part or all of the colon and the rectum [1]. 
Generally, both CD and UC patients present similar clinical symptoms (e.g. diarrhea, 
abdominal pain, GI bleeding, and weight loss).  Duerr et al. reported that genetic risk 
factors play a major role in the prevalence of IBD and risk of IBD development is 
increased by 5-30% in families of affected individuals. Interestingly, Tysk et al. found 
that the risk of phenotypic concordance in monozygotic twins with CD renged from 50-
75% in the second twin. However, they did not detect the same relation in UC patients 






this disorder compared to UC patients. In both studies, the authors suggested that other 
risk factors, including environmental factors, play an important role in UC and CD 
pathogenesis. 
In addition, many researchers have looked of the probability of CRC, a side effect of 
long-term chronic inflammation, in UC and CD patients.  They reported that probability 
of CRC in UC patients increased from 2% after 10 years of disease to 18% after 30 years 
compared to patients with CD that showed 2.9% risk of CRC at 10 years, which 
increased to 8.3% after 30 years of disease [18-20]. 
 
1.1.3. Manifestations of IBD  
1.1.3.1. Intestinal dysfunction in intestinal inflammation 
Recent studies reported multiple pathogenic factors that are involved in the prevalence of 
IBD for both CD and UC. Some of these pathogenic factors are:  
1. Qualitatively and quantitatively abnormal gut microbiota  
2. Largely dysregulated immune response. 
Chassaing’s study shows that such qualitative and quantitative changes in composition of 
the gut microbiota occur at the microbiological level in both CD and UC patients by 
reducing the complexity of commensal bacteria [21]. Former studies indicated the 
presence of high levels of immune reactivity against microbial antigens in patients with 
IBD. Murdoch et al. reported serum antibodies against microbial antigens in CD patients 






abnormal gut microbiota in UC patients compared to CD patients [23]. Additionally, 
Halstensen’s results pointed out that an antibody-mediated immune (autoimmune) 
response in UC patients could act as a pathogenic mechanism for epithelial impairment 
and accompanying inflammation [24]. 
The mucous layer is known to be the first line of protection against injurious agents in the 
gut lumen in healthy cells. In both forms of IBD, intestinal mucosa and intestinal 
epithelial cells (IECs) could be injured, resulting in intestinal permeability changes. IECs 
could be the main target for injury in IBD patients and these alterations may decrease 
humoral protective properties [25]. The study of Bjarnason et al. showed that intestinal 
permeability in patients with active CD is increased, causing unusual infiltration (by 
measuring the urine excretion of 51-chromium-labeled ethylenediaminetetraacetate) [26]. 
Importantly, intestinal permeability disorder is directly related to higher risk of acute 
cases of IBD [27]. For example, Pineton et al. demonstrated that infiltration of both 
neutrophils and macrophages into the intestinal mucosa is present in patients with chronic 
intestinal inflammation and disorders of IECs [28]. Moreover, antigen production is 
important for immunoregulation of healthy intestinal cells and different reports suggested 
the existence of possible abnormalities of IEC antigen-presenting capacity in IBD. Turner 
reported a direct relationship between intestinal permeability and IBD 
immunopathogenesis [29]. As adequate balance in the regulation of intestinal mucosal 
barrier is essential for normal cell function in the absorption of nutrients and waste 
secretion, any disruption of the mucosal barrier function can change the absorption of 
nutrients and microbial products that may lead to inflammation, as is the case in IBD. In 






induce oxidative damage in intestinal mucosa creating an imbalance in the redox status, 
which exacerbates inflammation in IBD [30]. 
 
1.1.3.2. Markers of inflammation and OxS in IBD   
As mentioned previously, unusual infiltration of macrophages into the intestinal mucosa 
and disorders of IECs triggered by the increasing intestinal epithelial permeability is 
present in intestinal chronic inflammation (IBD) [31]. ROS generated by these activated 
inflammatory cells could cause oxidative damage in intestinal mucosa. In addition, some 
studies present OxS as the most probable cause for the pathogenesis of human IBD [32, 
33] OxS is an imbalance between anti-oxidant defense and the production of ROS such as 
superoxide, hydrogen peroxide, hydroxyl radical and peroxynitrite disturb the redox 
homeostasis. Intermediate levels of ROS cause apoptosis, while imbalance due to 
overproduction of ROS and free radicals can decrease antioxidant defense causing 
necrosis and is harmful to cellular biological processes and tissue functions [34].  
 
Erichsen et al. and Rezaie et al. revealed that ROS levels vary under different conditions 
that could act by activating biological mediators (pro-oxidants or antioxidants). Low ROS 
levels were observed under physiological conditions whereas high ROS concentrations 
were noted under pathophysiological conditions. High concentration of ROS can oxidize 
nucleic acids (nuclear and mitochondrial DNA), or cause lipid peroxidation and protein 
damage [35, 36]. On the other hand, previous results demonstrate that low ROS 






pathways) and defense arising from endogenous and exogenous antioxidants, could be 




 Beneficial and harmful biological ROS pathways. Adapted from Figure 4.
Kawagishi and Finkel [38]. The high levels of ROS can provoke host defense 
pathways that cause decreased ROS levels. On the other hand, continued high 
levels of ROS can cause intracellular injury by stimulating autophagic 
clearance of damaged proteins or organelles.  
 
Free radicals having contact with iron can potentially develop into intestinal 






implicating transition metals leads to the production of reactive nitrogen species in UC 
[40, 41]. Kruidenier et al. also confirmed that OxS metabolite-mediated damage plays a 
role in the pathophysiological mechanisms of intestinal inflammation [42]. Patients with 
active CD are characterized not only by inflammation, but also by OxS markers along 
with decreased antioxidant status. Oxidative parameters can decrease to normal values 
when the disease is controlled and the patient is clinically stable [43]. The exaggerated 
ROS can directly damage the IECs while provoking the generation of several 
proinflammatory mediators, such as interleukin-1β (IL-1β), tumour necrosis factor alpha 
(TNF-α), IL-8 and IL-6 [44, 45]. In turn, these inflammatory mediators generate 
hydrogen peroxide and OxS in the IBD. 
Interestingly, it has been reported that the pro-inflammatory cytokine TNF-α provokes 
the production of mitochondrial oxidants (ROS) [46]. Consequently, these abnormal 
levels of ROS and proinflammatory cytokines work as activators of transcription factors 
like nuclear factor- kappa B (NF-𝜅B). In turn, stimulation of NF-𝜅B can promote further 
TNF-α production. These pathways lead to an abnormal cycle of extreme production of 
OxS [47, 48], which can cause a malfunctioning of the intestinal epithelial barrier.  
Prevention of NF-𝜅B activity can preserve intestinal membrane integrity [45, 49], while 
NF-𝜅B activation may upregulate oxidant-induced inducible nitric oxide synthase (iNOS) 
with damaging consequences such as cytoskeletal oxidation-nitration and monolayer 








 Role of some markers of OxS and inflammation in IBD. Figure 5.
Adapted from Zhu and Li [50]. As shown, the interaction between 
inflammation and OxS triggers ROS/RNS-generating systems with harmful 
consequences for patients with IBD. 
 
Pro-inflammatory cytokine TNF-α may also locate in the mitochondria and affect its gene 
expression [46]. Moreover, the expression of cytochrome (Cyt) C oxidase and Cyt b 
mRNA could be stopped due to mitochondrial contact with TNF-α. The resulting 
decreased expression of Cyt C oxidase and Cyt b mRNA may even decrease the 
regulation of mitochondrial biogenesis [51]. Disturbances in the modulation of NF-𝜅B 
alter the control of prostaglandin metabolism with an impact on inflammation and cancer 
[52]. The cyclooxygenase (COX) is a fundamental enzyme responsible for the conversion 
of arachidonic acid to prostaglandins [53]. The two identified forms of the COX enzyme, 






proinflammatory cytokines at the site of inflammation [54]. The role of COX-2 in the 
production of excessive inflammatory mediators such as prostaglandins has been studied. 
This inflammatory mediator mediates pain, assists in inflammatory activities and 
damages the integrity of the colon. 
Importantly, nonsteroidal anti-inflammatory drugs and certain other anti-inflammatory 
agents act via the inhibition of the COX enzymes [54]. Similarly, the anti-inflammatory 
activities of bee venom could inhibit COX-2 expression and block powerful pro-
inflammatory cytokines and other indicators of the inflammatory process (TNF- α, and 
IL-1β) [55] 
In IBD, oxygen radicals, especially superoxide and hydroxyl radicals are responsible for 
cell and tissue damage [56]. ROS within peripheral leukocytes cause DNA damage and a 
reduction in plasma antioxidant defence, observed in both CD and UC patients. One 
important marker for lipid peroxidation is malondialdehyde (MDA). It increases in 
plasma [57] and colonic biopsies [42] of CD patients. Two other non-invasive markers of 
lipid peroxidation such as breath output (CO2) and pentane excretion (urine) were 
increased in CD patients and were correlated with disease activity [58]. 
In general, endogenous and exogenous antioxidant defense scavenges free radicals and 
prevents OxS. For example, catalase, glutathione (GSH), glutathione peroxidase (GPx), 
glutathione reductase (GR), glutathione-s-transferase, superoxide dismutase (SOD), and 
dietary antioxidants (e.g. vitamines C, E, A) can control free radical-induced tissue injury 
by preventing the formation of radicals or supporting their disintegration [32, 35, 59-61]. 
Some studies show that the levels of principal antioxidants in the intestinal mucosa from 







1.2. Mitochondria  
Mitochondria are cytoplasmic organelles found in most eukaryotic cells with aerobic 
respiration, except in the red blood cells, and they are key players in cellular respiration. 
Mitochondrial population, size, mass and composition are diverse in different cells and, 
in fact, they correlate with baseline cellular metabolic state [62]. Mitochondria hold their 
own genetic material and metabolic system [63]. In healthy cells, mitochondria are about 
1-10 µm long, situated near the nucleus, and the main producers of energy [64]. This 
energy is produced in the form of adenosine-5'-triphosphate (ATP) by a process called 
oxidative phosphorylation (OXPHOS) and is consumed by the cells for different required 
biological processes (e.g. cellular metabolism) [65].   
 
1.2.1. Mitochondrial structure  
Mitochondria have a rod shaped structure and are found in all plants, animals, fungi, and 
most protists. Most cells have a large mitochondrion but some active cells have hundreds 
or even more mitochondria depending on the levels of cellular metabolic activity. As 
shown in Fig.6, the mitochondria have two protein-containing phospholipid membranes: 









 Schematic mitochondrial structure. Taken from The New Figure 6.
Zealand Biotechnology Learning Hub, 2009. 
 
The outer mitochondrial membrane covers the entire organelle, is permeable to small 
molecules, ions, and energy molecules like ATP and ADP molecules, and it acts as a 
main signaling center in all animal and human cells [68]. On the other hand the inner 
membrane has a more complex structure and is strictly impermeable. It is composed of 
crucial proteins such as enzymes that are involved in the main mitochondrial functions. 
The inner membrane is folded into structures called cristae, which increase surface area 
for cellular respiration and ATP production [69, 70]. The small space between the inner 
and outer membrane is called the intermembrane space while the space within 
mitochondria is called mitochondrial matrix, which holds, in humans, several copies of 






and IV and the ATP synthase complex), 2 RNAs, 22 transfer Ribonucleic Acids and 2 
Ribosomal RNAs that are required for mitochondrial DNA translation [26]. The RNA 
polymerase, the mitochondrial transcription factor A (mtTFA) and two mitochondrial 
transcription factors, mtTFB1 and mtTFB2 are part of the process of the transcription of 
mitochondrial genome [71]. The mitochondrial genome (mt genome) contains six main 
genome types that are classified in several ways such as the size, shape of DNA 
molecule, number of encoded genes, presence of cryptogenes, and editing of primary 
transcripts [72]. Some cellular metabolic processes taking place in the mitochondrial 
matrix include fatty acid beta-oxidation (FA β-oxidation), tricarboxylic acid cycle, heme-
synthesis, and iron-sulfur cluster formation [73]. Different mitochondrial enzymes, found 




1.2.2. Mitochondrial function  
Mitochondria are multifunctional organelles that interact with other organelles. 
Receiving, integrating and transmitting signals are part of their regulation. It is important 
to mention that the different structural compartments of the mitochondria play important 
roles in the way mitochondria function. The mitochondria are known to be the main 
powerhouse of the cell by participating in several cellular metabolic activities and 
specific functions such as ATP production though FA β-oxidation, and OXPHOS, 






there are five main mitochondrial functions noted to be essential for the dynamics of 
mitochondrial structure and function. These functions are mitochondrial biogenesis 
(controling mitochondrial population), mitophagy process (through which the cell 
removes damaged mitochondria), mobility of mitochondria, redox signaling and the 
regulation of Ca2+ signaling, which influences oxidative metabolism and apoptosis [78].  
 
1.2.2.1 Fatty Acid Beta-oxidation 
As mentioned before, one of the functions of mitochondria is the production of energy by 
FA β-oxidation, another non-direct mechanism of ATP production [79]. This process 
takes place in the matrix of mitochondria and provides energy in the absence of glucose 
catabolism.  Before long chain FA can enter the mitochondria, the cytoplasmic enzyme 
acyl-CoA synthetase activates FAs by binding them to coenzyme A. Acyl-CoA 
molecules are then able to enter the carnitine cycle in order to be converted into acyl-
carnitine, thereby transiting through mitochondrial membranes prior to reconverting into 
acyl-CoA in the mitochondrial matrix.  Short- and medium-chain FAs can enter into 
mitochondria directly. In the β-oxidation cycle, Acyl CoA is oxidized into acetyl-CoA 
and then integrates the citric acid cycle (Krebs cycle) to produce more ATP [80] as 
shown in Fig.7. Two other final products of the β-oxidation cycle, NADH and FADH2, 







 Fatty acid β-oxidation. Taken from Kleme et al. [74]. Figure 7.
 
The electrons that are also produced by the β-oxidation cycle are transfered by electron 
transfer flavoprotein: ubiquinone oxidoreductase system from acyl-CoA dehydrogenases 
(ACADL) to an ubiquinone pool (coenzyme Q) located in the inner membrane of 
mitochondria [82] to participate in different complexes of the respiratory chain (RC) to 







1.2.2.2 Glycolysis, Krebs cycle, Electron Transport Chain Complexes (OXPHOS) 
and ATP production  
Overall, ATP production occurs by three different pathways that consist of anaerobic 
glycolysis, Citric acid cycle (Krebs cycle) and mitochondrial OXPHOS in the matrix of 
mitochondria [83].  
Glycolysis and citric acid cycle are the catabolic pathways that breakdown glucose and 
other fuel molecules to produce energy. Glycolysis takes place in cytosol and starts with 
breaking down glucose into two molecules of pyruvate. Pyruvate is then oxidized to 
carbon dioxide in the citric acid cycle that occurs in the mitochondrial matrix. The 
electrons that are produced in glycolysis and the citric acid cycle are carried and 
transferred via NADH to the electron transport chain [84] to produce more ATP. In 
addition, a final way that mitochondria contribute to ATP production is by electron 
transport on the inner membrane through a chain of multiprotein complexes (I-IV), two 
mobile carriers (coenzyme Q and Cyt C) and ATP synthase. Electron donors (i.e. NADH, 
FADH2) transfer the electrons that are required for these vital complexes. In the phase of 
electron transfer (mitochondrial OXPHOS), electrons received from electron donors are 
transmitted to O2 through complexes-I, -III, and -IV. Furthermore, as shown in Fig.8, this 
electron production causes a proton gradient in the mitochondrial inner membrane along 
with the formation of water and ATP that is synthesized through complex V (ATP 
synthase) [85-87].   
Under normal conditions, mitochondrial respiratory system produces more than 95% of 
ATP [88] consumed by the cells for different biological processes such as cellular 







 Mitochondrial site and role of the RC complexes. Taken from Figure 8.
Bayir and Kagan [89] 
 
1.2.2.3 Apoptosis regulation 
In animal and human cells, apoptosis is known as a normal and healthy pathway that is 
otherwise referred to as programmed cell death in all steps of cell development. There are 
two different mechanisms for the apoptotic pathways: the mitochondrial pathway and the 
non-mitochondrial pathway. In recent years, numerous apoptosis related factors of the 
mitochondrial apoptotic pathway have been discovered [89]. They integrate different 
types of endogenous and exogenous pro-apoptotic signals from other organelles, 
including the nucleus, cytosol and lysosomes, as well as exogenous factors such as 
certain viral proteins [90]. 
During apoptosis, specific proteins are released from the mitochondria to promote cell 






space of the mitochondria in healthy cells, is activated in inflammation and is essential to 
respiration [90-92]. Cyt C is a small electron carrier protein that assists in cell energy 
production by transferring electrons from complex III to complex IV. Maintenance of Cyt 
C inside mitochondria is vital due to the fact that its release into the cytosol can result in 
apoptosis [93]. 
Another apoptogenic factor present in the intermembrane space of the mitochondria in 
normal cells is apoptosis-inducing factor (AIF) that initiates apoptosis by activating a 
caspase-independent pathway. AIF is a positive natural regulator of apoptosis by 
inducing DNA fragmentation and chromatin condensation [91]. In the normal cells, 
AIF’s main role is to protect mitochondrial membrane permeability and support 
OXPHOS [94]. As studies demonstrated, both Cyt C and AIF apoptogenic mitochondrial 
proteins are released into the cytoplasm causing a cascade of pathways (activation of 
caspase 9 leading to changes in caspase 3, 6 or 7 activity), which activate the 
mitochondria-mediated apoptotic pathway and finally drive apoptosis [90] as illustrated 







 Graphic picture of role of mitochondrial permeability transition Figure 9.
pore (MPTP) opening in apoptosis. Adapted from Saenz et al. [95] 
 
Other major players of apoptosis are members of B-cell lymphoma 2 (Bcl-2) proteins, the 
imbalance of which may favor the apoptotic pathways in both healthy and compromised 
cells [90]. The anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax are the 
most important members of this family. They are normally located in the cytosol and they 
are the main regulators of the mitochondrial apoptosic process by controlling 






remain in the space between the inner and outer membranes of mitochondria 
(intermembrane space). In physiological healthy conditions, anti-apoptotic Bcl-2, the 
protein bound to the outer membrane, inhibits mitochondrial apoptosis. On the other 
hand, when the pro-apoptotic Bcl-2-associated X (Bax) protein is translocated to the 
mitochondria, it causes apoptosis [90, 96]. In addition, the ratio of pro- and anti-apoptotic 
Bcl-2 family proteins (Bax/Bcl2) establishes the sensitivity of cells to many apoptotic 
factors, as shown in schematic Fig.10 [91, 97]. 
 
 
 The roles of pro- and anti-apoptotic factors in mitochondrial Figure 10.
permeability and apoptosis. Adapted from Kwak [98]. This image 
demonstrates that overexpression of pro-apoptotic Bcl-2 family proteins 
releases Cyt C, AIF and some caspases from mitochondria. Similar situation 






mitochondrial Ca2+ can cause apoptosis and cell death. 
 
1.2.2.4 ROS generation and detoxification  
In addition to energy production and regulation of programmed cell death, another 
important function of mitochondria is the generation of ROS, which have vital roles in 
cell signalling and homeostasis. Mitochondria are responsible for producing more than 
90% of total ROS found in cells [99]. 
ROS can be generated by mitochondria as a result of normal electron transport and also 
during mitochondrial dysfunction. This occurs when electrons escape from the electron 
transport chain to generate superoxide anions. Several other proteins that participate in 
glycolysis, mitochondrial electron transport, β-oxidation and the Krebs cycle can produce 
superoxide, hydrogen peroxide and other ROS. These proteins include CI, CII, CIII, 
dihydro-orotate dehydrogenase, pyruvate dehydrogenase, aconitase, 2-oxoglutarate 
dehydrogenase and Sn-glycerol-3-phosphate dehydrogenase. Furthermore, other 
mitochondrial proteins such as  monoamine oxidases and p66shc/ Cyt C may contribute 
to ROS production [100]. ROS overproduction can lead to OxS by causing oxidative 
deterioration of proteins, lipids and DNA.  
In healthy cells, some endogenous systems of antioxidant enzymes, including SOD, GPx, 
GR, and catalase, act as the primary defence mechanism, keeping ROS at physiological 
levels [101]. These enzymes can help remove excess ROS. SOD1 enzyme is located in 
the intermembrane space and cytosol, SOD2 in mitochondrial matrix and SOD3 in 






hydrogen peroxide [102]. Subsequently, GPx, another enzyme involved in detoxification, 
decays hydrogen peroxide and lipoperoxides that participate in lipid peroxidation. Toxic 
hydrogen peroxide can also be decomposed to water and O2 by the catalase enzyme 
[103]. 
 
1.2.2.5  Ca2+ homeostasis  
Ca2+ channels are responsible for controlling Ca2+ release from the endoplasmic 
reticulum (ER) in response to biochemical signals. Also, mitochondrial Ca2+ is the 
principal functional regulator of mitochondrial ATP output and cellular ATP needs [77, 
104]. OxS can result in higher level of mitochondrial Ca2+ and thus increased cytosolic 
Ca2+ [105]. In this case, Ca2+ overload can cause over-production of ROS, which forces 
apoptosis [106-109] by MPTP opening and Cyt C release. ER are linked by 
mitochondria-associated membranes (MAMs) and the communication between these two 
organelles can take place through Ca2+ signaling.  
Some important functions of mitochondria depend on the MAMs membrane that controls 
the transport of metabolites and proteins. Furthermore, this membrane helps transfer 
lipids and mitochondrial RC complex products that participate in OXPHOS and ATP 
production [66, 110].  
1.2.3. Mitochondrial dysfunction 
Mitochondrial form and function in healthy cells are important for producing various 






focused on mitochondrial dysfunctions in association with various diseases/disorders 
including diabetes, cancer, muscular disorders, cardiomyopathy, deafness, lactic acidosis, 
and skeletal disorders. Furthermore, it is thought that mitochondrial dysfunction may 
participate in inflammatory pathogenesis [111]. 
Several studies have reported that changes in mitochondrial structure and/or function may 
lead to mitochondrial dysfunction and this has been observed in the intestinal Caco-2/15 
cell line [112] and animal models [113].  Likewise, Rodenburg et al. study confirmed that 
the IECs from an animal model of colitis demonstrated unusual mitochondrial structure 
[113]. Morphological changes in mitochondrial form and function were found in human 
intestinal cells isolated from patients with IBD. These mitochondria were swollen and 
had abnormal cristae [114, 115]. Additionally, the study by Nazli et al. reported that 
patients with intestinal inflammation presented abnormal mitochondrial structure in their 
intestine [116]. As shown in Fig.11, in inflammatory conditions, the mucus layers as well 
as the antimicrobial peptides are diminished and the intestinal epithelial lumen is exposed 
to intestinal microbiota and luminal antigens. Mitochondria become irregular with a 






           
         
 
 Intestinal homeostasis disorders in mitochondrial dysfunction. Figure 11.
Adapted from Novak and Mollen [78]. (A) In homeostatic intestine, healthy 
mucus protects the epithelial cells from lumen contents, and antimicrobial 
peptides are produced and released as well. The mitochondria are perfectly 
shaped and the tight junctions prevent luminal antigens from crossing the 
epithelial barrier. Cellular antioxidants control basal ROS and leukocytes 
protect the lamina propria.  (B) In inflammatory conditions, the mucus layers 
as well as the antimicrobial peptides are diminished and the intestinal epithelial 
lumen is exposed to intestinal microbiota and luminal antigens. Mitochondria 









1.2.3.2. Mitochondrial respiratory chain (ATP production) and β-oxidation in IBD 
In order to understand the mechanisms of mitochondrial dysfunction in diverse disease 
processes, researchers have focused on mitochondrial pathways, including RC and ATP 
production, ROS generation, and autophagy.  Many studies have shown that assembly 
complications or structural problems, which can occur in the process of ATP production 
within five multiprotein complexes (complexes I to V) and in the mobile electron carriers 
(coenzyme Q and Cyt C), would cause mitochondrial dysfunction and thus reduce ATP 
generation. In addition, serious disorders in the OXPHOS complex pathways can induce 
a series of complications, including electron leakage, increased formation of toxic OxS, 
and highly abnormal production of apoptotic factors. Furthermore, these abnormalities 
may finally cause oxidative stress, cell death and degeneration of the related tissues [65, 
117]. Accordingly, several studies have shown decreased levels of ATP in the intestinal 
cells of animal models with intestinal inflammation and in patients with IBD (compared 
to healthy condition) [118-120]. Bar et al. examined mucosal OXPHOS activities and 
levels of ATP in mice and suggested that mice with higher mucosal ATP levels show less 
inflammation in experimental colitis. This study also showed that the colonic tissues in 
mice with higher mucosal ATP levels had higher levels of NF-𝜅B. Increased NF-𝜅B 
activity in colonic tissues may help to preserve mucosal barrier in IBD [121]. 
Butyrate, a short chain fatty acid (SCFA), is the preferred energy source for colonic 
epithelial cells and highly significant for maintenance of normal mucosal function. This 
short carbon FA is metabolized through the β-oxidation pathway occurring within 
mitochondria. Results from the experimental colitis in mice (with DSS) [122] and the UC 






in UC.  Also morphological changes in the mitochondria can affect β-oxidation of SCFA 
in inflamed IECs [124]. De Preter et al. demonstrated reduced butyrate oxidation rate in 
active UC patients by evaluating their colonic biopsies compared with healthy controls 
[125]. More recently, another study by De Preter et al. indicated that butyrate uptake and 
its colonic metabolism in UC were significantly diminished compared with healthy 
controls and this was due to the reduced expression of butyrate transporter and enzymes 
participating in the β-oxidation pathway of butyrate [126]. 
 
1.2.3.3. Oxidative stress and mitochondrial dysfunction in IBD 
Various components and molecular functions within mitochondria can become targets for 
oxidative impairment. Indeed, OxS occuring in mitochondria can cause serious 
intracellular impairments such as alterations of mitochondrial membrane function [30, 
127]. As mentioned before, mitochondria are key players in the control of OxS due to 
their production of free radicals. However, they are able to balance this ROS production 
with their antioxidant defense system. Although the molecular mechanisms of 
mitochondrial intestinal injury in IBD are not completely clear, many studies have 
demonstrated that the presence of OxS, overproduction of colonic oxidants and 
imbalance between ROS production with mitochondrial antioxidant defense system can 
play a major role in these damages and disease processes. 
Reed et al. demonstrated that a high level of ROS in the mitochondria may lead to an 






MPTP. This permeability also leads to a decreased mitochondrial membrane potential 
[90]. 
Increased levels of mitochondrial OxS and defects in the intestinal epithelium were noted 
in mice with experimental colitis [128] and in patients with IBD [119, 129].  
Furthermore, other studies demonstrated that ROS produced by mitochondria can cause 
damage to mitochondrial DNA bases that result in an impairment in coding of complexes 
I, III, and IV and the ATP synthase complex protein involved in energy production for 
healthy cells and tissues [130, 131]. 8-oxoguanine (8-oxoG) is a mutagenic base by-
product generated by exposure to ROS in human and murine models. Healthy cells 
produce different repair enzymes and 8-oxo DNA glycosylase (OGG1) is a primary 
enzyme responsible for cell protection by removing 8-oxoG from mitochondrial DNA 
backbone [71]. The study of Chang et al. demonstrated that the augmentation of 8-
hydroxy-deoxy-guanosine (8-OHdG), provoked by the absence of repair via OGG1, 
amplifies mutations and mitochondrial dysfunction, thereby resulting in the initiation of 
apoptotic cell death [132]. 
 Damage of 8-OHdG from both CD and UC patients was examined by measuring the 
levels of 8-OHdG in the blood as a marker of OxS. The results showed that free radicals 
causing mitochondria DNA (mtDNA) damage within peripheral leukocytes increased and 
plasma antioxidant defenses decreased [7, 61]. In addition, D'Inca et al. observed that 
colorectal biopsies from UC patients showed oxidative mtDNA damage that was 
measured by production of  8-OHdG [133]. Also, Lih-Brody et al. have shown the 
dysfunction of intestinal homeostasis, DNA modifications and damage due to 






Overall, mtDNA damage can cause many serious problems for cells due to increased 
ROS production and disrupted electron transport chain [84]. In this regard, mutated 
mtDNA can generate increased OxS in the mtDNA of damaged cells due to higher 
production of superoxide radicals [135, 136]. Accordingly, mitochondrial proteins could 
be potential biomarkers in the pathways of several human diseases, and mitochondria 
may become a promising target for antioxidant-delivery strategies. 
 
1.2.3.4. Additional mechanisms for apoptosis and mitochondrial dysfunction in IBD 
An abnormal MPTP opening can liberate Cyt C into the cytosol. Unusual release of Cyt 
C with some other mitochondrial pro-apoptotic proteins could be the immediate signal of 







 Schematic image of mitochondrial ROS’s roles in apoptosis. Figure 12.
Adapted from Qiu et al. [137]. This image demonstrates that increased ROS 
leads to increased permeability of the outer mitochondrial membrane and 
decreased mitochondrial membrane potential. This may cause apoptosis by 
activating a series of pro-apoptotic pathways. 
 
During apoptosis, specific proteins are released from the mitochondria to promote cell 
death. 
One of the main pro-apoptotic proteins activated in inflammation injury is Cyt C, a 
protein that is localized in the intermembrane space of the mitochondria in healthy cells 
and is essential to respiration [90, 91]. An abnormal MPTP opening can cause necrosis or 






activating a series of caspases. Because of this cascade of caspases, the apoptotic signals 
release and finally provoke caspase-dependent apoptosis with activation of caspase-9, 
which then activates caspase-3. Unusual release of Cyt C with some other mitochondrial 
pro-apoptotic proteins could be the immediate signal of apoptosis causing mitochondrial 
dysfunctions [92]. 
MPTP malfunction due to high levels of ROS also initiates the release of AIF into the 
nucleus in the mature soluble form (AIFsol), where it provokes nuclear apoptosis in 
a caspase-independent manner and finally causes DNA damage [138]. High levels of 
ROS and increased expression of pro-apoptotic Bcl-2 family proteins, including Bax, can 
also cause cell death [90, 91]. In a study by Arab et al, to evaluate colonic apoptosis, the 
mRNA expression of Cyt C, Bax, Bcl-2 and caspase-3 was analyzed in trinitrobenezene 
sulphonic acid induced colitis in rats. This study showed increased mRNA expression of 
caspase-3, the pro-apoptotic Cyt C and Bax with downregulation of Bcl-2 [139]. 
In another study by Taha et al, the effect of oxidative stress on mitochondrial dysfunction 
in IBD was studied in the Caco-2/15 cell line. In this study Caco-2/15 cells were exposed 
to iron-ascorbate, which produces oxygen radicals and can contribute to lipid 
peroxidation in IBD. The result of this study indicated that the level of AIF and Cyt C 
proteins increased in Caco-2/15 cells after iron-ascorbate administration compared with 
the control group [112]. 
 
1.2.3.5. Ca2+ homeostasis and mitochondrial dysfunction in IBD 






Ca2+ signaling) can be affected by ROS concentration, pro-inflammatory cytokines and 
also by the anti-apoptotic protein Bcl-2. Recently, Pinton et al. have suggested that the 
anti-apoptotic protein Bcl-2 could reduce ER Ca2+ levels, hence reducing mitochondrial 
Ca2+ uptake [77]. Alteration in ROS concentration can affect Ca2+ channel activity and 
change the concentration of mitochondrial Ca2+. Also, malfunctions in Ca2+ signaling 
and Ca2+ concentrations may lead to increased risk of cell damage and death [77]. 
Qureshi et al. noted that disorders in intracellular Ca2+ mobilization could cause 
increased NF-κB activity and result in dysmotility of colonic smooth muscles in murine 
models of experimental colitis [140]. In an investigation by Di Sabatino et al., it has been 
found that a reduction in pro-inflammatory cytokine release can occur by prevention of 
mitochondrial Ca2+ overload in inflamed intestinal cells. In addition, prevention of 
mitochondrial Ca2+ overload by activation of Ca2+ channel inhibitors can result in 
diminished mitochondrial ROS accumulation, increased mitochondrial energy production 
and correction of mitochondrial oxidative stress-mediated disorders [141]. 
 
 
1.3. Therapeutic intervention: antioxidants targeting 
mitochondrial dysfunction 
1.3.1. Antioxidant and anti-inflammatory agents 
A phenolic antioxidant is a molecule with a strong capacity to reduce or stop the 






antioxidants play the main role in stabilizing or disabling free radicals before they 
become dangerous by attacking the closest cells and cellular components [142].   
In recent years, flavonoids and other polyphenols, the so called bioactive molecules with 
antioxidant properties, have become the subject of many studies to determine their 
properties to prevent or cure oxidative damage caused by OxS, nitrogen species 
metabolism and other markers for oxidative damage [143, 144]. Many studies have 
shown that, in healthy and pathologic cell conditions, the endogenous antioxidants such 
as SOD, catalase [145] and GPx enzymes play an important role in keeping the balance 
between oxidative damage pro-oxidants and endogenous defense mechanisms. Non-
enzymatic antioxidant substances are also responsible for the control of ROS overload 








 Schematic illustration of oxidants and antioxidants imbalance, Figure 13.
oxidative damage, and chronic diseases. Adapted from Arulselvan et al. [148]. 
 
Endogenous enzymatic and non-enzymatic antioxidants also have an important role in 
decreasing OxS [149]. Recently, several studies have observed that natural antioxidants 
from several plant sources, including flavonoids and phenolic compounds play a 
preventive role in protecting against the generation of free radicals. In addition, 
flavonoids and phenolic compounds act as anti-inflammatory factors by inhibiting two 
main signalling pathways including NF-𝜅B and mitogen-activated protein kinases 
(MAPKs) that play a part in production of different proinflammatory mediators [149]. 
 
1.3.2.  Polyphenols 
1.3.2.1. Structural diversity and dietary sources of polyphenols 
Polyphenol compounds are most commonly found in fruits, vegetables, cereals, and 
beverages [150]. These components have a simple structure and hold one or more 
benzene rings with 2 or more hydroxyl groups. In addition, polyphenols are considered 
the most available antioxidants in the human daily diet with important biological 
properties, including anti-inflammatory and immunomodulatory features. Presently, 
elegant studies have shown that more than five hundred different polyphenols are 
regularly found in daily foods while also providing important information about 
polyphenol consumption and bioavailability [151]. Dietary polyphenols from different 






therapeutic effects and preventive properties against several chronic diseases, including 
cardiovascular disorders, degenerative diseases, diabetes, osteoarthritis and GI diseases. 
Polyphenols are classified into diverse groups according to their different chemical 
structures, degree of oxidation, amplitude of polymerization and substitutions of the basic 
skeleton [152]. The two principal subgroups of polyphenols are flavonoids and non-
flavonoids, and each subgroup is divided into six different subclasses [151]. The two 
subgroups are categorized by the existence of different numbers of phenolic rings, along 
with two or more hydroxyl substitutions. In particular, the flavonoids contain two 
benzene rings linked by a linear three-carbon chain to form and produce different kinds 
of flavonoid subclasses. This characterization is based on the oxidation state of the 
central pyran ring in flavonoid molecules. Some common groups of flavonoids are 
flavones, isoflavones, flavonols, flavanones, flavanols, anthocyanins, and anthocyanidins. 
The nonflavonoids contain phenolic acids, lignans and stilbenes [152, 153].  
“Aglycone”, the simple phenolic structure of polyphenols could be attached with 
carbohydrates and organic acids to produce “glycone” structures. Simple phenolic 







Polyphenols from food with simple phenolic compounds such as gallic acid, ellagic acid, 
catechin, eugenol, vanillin, caffeic acid, ferulic acid, apigenin, quercetin, gingerol, 
kaempferol, myricetin, resveratrol, rutin, naringenin, and cyaniding are factors that 
modify and prevent inflammatory response, as well as alter gut microbiota [154, 155].  
1.3.2.2. Biological functions of polyphenols 
Polyphenols play a key role in cell health through their antioxidant actions through two 
different pathways, ‘‘ROS-removing level’’ and ‘‘ROS formation level’’. The first 
mechanism shown in Fig.14 constitutes a direct pathway for ROS-inhibition. The ‘‘ROS-
removing level’’ can act through 3 different mechanisms: ROS-scavenging 
(electron/hydrogen transfer), production of ROS-removing enzymes (e.g. SOD, catalase, 
GPx) and production of endogenous antioxidant-synthesizing enzymes (e.g. glutathione 
synthase). Furthermore, the second antioxidant mechanism of polyphenols is a direct 
action of polyphenols that inhibits the metal-dependent formation of free radicals (iron 
and copper) and decreases or controls ROS-forming enzymes (e.g., XO, NOX, LOX, 









 Classification of the polyphenols antioxidant related action. Figure 14.
Adapted from Sandoval et al. [156] 
 
The focus of this thesis is on the antioxidant and anti-inflammatory actions of 
polyphenols given their potential benefits in IBD. [157, 158]. 
 
1.3.2.3. Apple polyphenols 
Apples are one of the richest sources of polyphenols.  In recent years, different studies 
have shown that daily intake of apple polyphenols and apple-derived polyphenolic 
products may inhibit or decrease chronic diseases including OxS-associated disorders, 
cardiovascular diseases and arthritic diseases. Furthermore, they have shown to preserve 






Apple polyphenols contain diverse structural models, such as hydroxycinnamic acids, 
flavonols (quercetin glycosides), dihydrochalcones (phloretin glycosides), chlorogenic 
acid, procyanidins, dihydrochalcones and flavan-3-ols (oligomericpro­cyanidins). The 
most prevalent groups of polyphenols present in apples are chlorogenic acid, 
procyanidins, and dihydrochalcones [160, 161].  
Several preclinical studies have demonstrated that apple polyphenols have the potential to 
protect or treat peptic ulcer by numerous intracellular and molecular activities [11, 162].  
Graziani et al. have observed that apple polyphenols inhibit expression of COX-2 mRNA 
and protein in gastric tissue. These polyphenols decreased the peroxidation of lipids in 
the tissue and caused a moderation in the level of MDA in gastric mucosa. In addition, 
apple polyphenols protected against xanthine-xanthine oxidase-induced damage and 
indomethacin-induced oxidative injury in human gastric epithelial cells by improving the 
antioxidant potential and preventing lipid peroxidation [11]. These results from human 
studies illustrate the powerful effects of polyphenols in reducing the risk of several 
chronic illnesses (e.g., cardiovascular disease, neurodegenerative disorders, diabetes, 
cancers, osteoarthritis, and GI diseases) or improving their symptoms. In this thesis our 
focus is to demonstrate the preventive and/or therapeutic potential of apple polyphenols 
in the management of IBD.  
 
1.3.3. Apple polyphenols in intestinal inflammation 
In different inflammatory diseases, including IBD, there is an increased expression of 






different studies have shown that both CD and UC are lifelong disorders that cause 
different challenges for the scientific and medical communities because of several 
unsolved problems, such as dramatically growing prevalence of IBD, absence of a cure, 
severe drug side effects, unresponsiveness to medical treatments, direct and indirect 
treatment costs and socio-economic burden as shown in Fig. 15 [163-165]. Recently, the 
illustration of biological and beneficial effects of polyphenols, in particular, apple 
polyphenols in the management of inflammation has captivated the attention and interest 
of researchers. These studies looked at the molecular mechanisms of action of the 
different natural elements [161, 166-168]. 
 
 
 Schematic description of main reasons for treating IBD patients Figure 15.







The preclinical study by Jung et al. demonstrated that apple polyphenols can inhibit the 
expression of pro-inflammatory cytokines and enzymes in human colonic epithelial cells 
by the prevention of interferon-gamma-inducible protein-10, IL-8-promoter, and of NF-
kB dependent signal transduction [161, 169].  Furthermore, apple polyphenols have also 
shown beneficial health effects in animal models of colitis by modulating the expression 
of MAPK, a signalling protein family. The modulation of this signalling pathway by 
polyphenols causes down-translation and down-transcription of proteins that are involved 
in the inflammatory response [128, 157]. 
Experimental aspirin-induced gastric ulcer presented gastroprotective effects of dietary 
intake of apple polyphenols.  These natural polyphenols caused up-regulation of GSH in 
gastric mucosa of rats. As we know, GSH in gastric mucosa has antioxidant activity. 
Also, apple polyphenols elevate the expression of glutathione-S-transferase P1 that acts 
as an enzymatic antioxidant in gastric tissue. In Paturi’s study, they also found that apple 
polyphenols cause overexpression of mucin-2 and trefoil factor-2 genes, which assist in 











2 RESEARCH PROJECT 
2.1. Hypothesis  
We hypothesize that: 
1.  Dried apple peel powder (DAPP) has the potential to prevent or reduce OxS and 
inflammation via the modulation of mitochondrial functions or/and structure in 
experimental colitis. 
2.  The resulting beneficial actions may contribute to the preservation of intestinal 
epithelium and homeostasis. 
 
2.2. Objectives 
As mitochondria are the major source and target of free radicals, while exhibiting various 
important functions, the aims of our study are to determine: 
•  Alterations in prooxidant/antioxidant balance and the status of inflammatory factors in 
association with intestinal microbiota and in response to DSS-induced colitis;  
• The contribution of DAPP to prevention and treatment of experimental colitis by fighting 
OxS, inflammation and mitochondrial derangements; 
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Diets rich in fruits and vegetables may reduce oxidative stress and inflammation via 
several mechanisms. These beneficial effects may be due to their high polyphenol 
content. The aims of the present study are to evaluate the preventive and therapeutic 
aspects of polyphenols in dried apple peel extract (DAPP) on intestinal inflammation 
while elucidating the underlying mechanisms and clinical benefits. Induction of intestinal 
inflammation in mice was performed by oral administration of the inflammatory agent 
DSS at 2.5% for 10 days. Physiological and supraphysiological doses of DAPP (200 and 
400 mg/kg/day, respectively) were administered by gavage for 10 days pre- and post-
DSS treatment. DSS-mediated inflammation caused weight loss, shortening of the colon, 
dystrophic detachment of the epithelium, and infiltration of mono- and 
polymorphonuclear cells in the colon. DSS induced an increase in lipid peroxidation, a 
down-regulation of antioxidant enzymes, an augmented expression of MPO and COX2, 
an elevated production of PGE2 and a shift in mucosa-associated microbial composition. 
However, DAPP normalized most of these abnormalities in preventive or therapeutic 
situation in addition to lowering inflammatory cytokines while stimulating antioxidant 
transcription factors and modulating other potential healing pathways. The 
supraphysiological dose of DAPP in therapeutic situation also improved mitochondrial 
dysfunctions. Relative abundance of Peptostreptococcaceae and Enterobacteriaceae 
bacteria was slightly decreased in DAPP-treated mice. In conclusions, DAPP exhibit 
powerful anti-oxidant and anti-inflammatory actions in the intestine and are associated 
with the regulation of cellular signaling pathways and changes in microbiota 
composition. Evaluation of preventive and therapeutic effects of DAPP may be clinically 










Inflammatory bowel diseases (IBD), clinically manifested as Crohn’s disease (CD) and 
ulcerative colitis (UC), represents a widespread, chronic and debilitating set of disorders 
characterized by aberrant inflammation and immune-mediated injury to the 
gastrointestinal tract (1). Despite the recent advances in the fields of IBD genetics and 
mucosal immunology, our understanding of the pathogenesis of IBD remains 
fragmentary. The most widely accepted comprehensive hypothesis encompasses three 
main factors: genetic predisposition, environmental influences and the loss of 
homeostasis between the intestinal microbiome and host immunity (2, 3). A disruption of 
immune tolerance to commensal bacteria and deregulation of the intestinal microbiota 
balance (dysbiosis) may result in gut inflammation, epithelial dysfunction and enhanced 
mucosal permeability (4). Although genome-wide association studies and meta-analyses 
have resulted in the discovery of an ever-increasing number of genetic susceptibility loci 
(5-7), the findings can only explain ~25% of the predictable heritability risk of CD. In 
addition, the complex, as yet poorly understood interaction of the aforementioned factors 
is ultimately believed to induce chronic relapsing of intestinal inflammation leading to 
the various clinical phenotypes of disease expression. Noteworthy, among environmental 
risk factors, diet is the most commonly implicated, as epidemiological studies have 
shown that different dietary macro- and micronutrients may play a role in CD (8).  
 
IBD significantly impacts on quality of life and accounts for a substantial financial 
burden to our health care system and to society (9, 10). Patients often require lifelong 
medication and the conventional treatment for IBD involves the use of corticosteroids, 
immunosuppressive agents, anti-tumour necrosis factor (TNF) antibodies and antibiotics 
(8-10). Some of these agents have been associated with the risks of infection and 
malignancy (11, 12), as well as numerous side effects (13-15). Moreover, not all patients 
are responsive to drug therapy. On the other hand, due to its perceived natural and 
healthy properties, pediatric and adult patients with IBD are increasingly using 
complementary and alternative medicine (16-19). It may reach 60% in adult IBD 
populations from North America and Europe (20). However, scientific evidence 
regarding their efficacy or safety remains inadequate, and the majority of studies have 
produced inconsistent results (21). If in the late 90's, the nutritional spotlight focused on 
the antioxidant capabilities of carotenoids, vitamins, and minerals, growing strong 
support has more recently been devoted to dietary polyphenols, secondary plant 
metabolites, ubiquitously present in fruits and vegetables, which represents a significant 
class within the family of phytonutrients. This rising scientific interest stems from their 
antioxidant capacity and their role in the prevention of certain cancers, diabetes and 
cardiovascular diseases (22-25). The resurgence of interest in the last decade is also 
aroused by their anti-inflammatory effects (26, 27). Although protective or preventive 
anti-inflammatory properties of a number of polyphenol species have been noted in IBD, 
the mechanisms of action underlying their health-promoting effects remain largely 
speculative. In addition, the quite unrealistic doses that cannot be reached in a common 
diet and the mode of administration (i.e., intraperitoneal) have prevented their 







The major aim of the present study was to investigate the preventive and therapeutic 
capacity of polyphenols isolated from dried apple peel extract (DAPP) in IBD-related 
disorders. We chose this fruit since the apple ranks second for the total polyphenol 
concentrations and had the highest portion of free polyphenols when compared to other 
fruits (16). Furthermore, 20% of polyphenols consumed from fruits are from apples in 
Canada and the United States (Statistics Canada, and Economic Research Service, United 
States Department of Agriculture, Food Availability, compilation MAPAQ). We also 
employed polyphenols from apples given their reported bioactivity and their presumed 
protecting role in reducing the risk of chronic diseases such as cancer, type II diabetes, 
cardiovascular disease, pulmonary disease and asthma (29). We especially selected 
DAPPs since they are more diversified and concentrated than those of the flesh (30). 
Indeed, in addition to the rich phenolic content (phloretin glycosides, phloridzin, and 
chlorogenic acid) in peel and fresh apples, the peel contains additional flavonoids that are 
not found within the fresh (30). 
To examine the preventive and therapeutic effects of DAPP, we employed the dextran 
sulfate sodium (DSS)-induced colitis mouse, a highly valuable and the most frequently 
animal model employed to investigate IBD pathogenesis in view of its simplicity, wide 
applicability and various advantages when compared to other animal models of colitis 
(31). It exhibits numerous characteristics that are similar to human colitis, including 
inflammatory response progression, clinical signs (diarrhea, occult blood, gross rectal 
bleeding, shortening of the colon), histopathological changes of the intestine, and 
modifications of intestinal microbiota (31). In the present investigation, we examined the 
DAPP effects by focusing on the induction of endogenous antioxidant status, neutrophil 
infiltration, eicosanoid-generating enzymes, cytokine-induced inflammatory response and 
gastrointestinal integrity protection. Insights into the mechanisms were gained by 
analyzing mitochondrial functions, transcription factors activation, transcriptomic 







MATERIALS AND METHODS 
DAPP extraction  
The phenolic compounds of apples (80 % McIntosh and 20% Northern Spy blend, 
Cortland, Empire, Ida Red, Jonagold and Spartan) were extracted by a method similar to 
that reported previously by Liu’s laboratory (30, 32, 33). Noteworthy, all the experiments 
were carried out using the same batch (e.g. one single extraction) of DAPP, helping to 
ensure comparative and correlative studies. 
 
LC-MS analysis of DAPP extract  
A reversed phase LC-MS method has been developed to separate and identify the mass 
and chemical structure of phenolic compounds derived from DAPP extract by ultra-
performance liquid chromatography system (UPLC) coupled to a QuanTOF mass 
spectrometer (MS/MS QTOF) equipped with an ESI source (UPLC-ESI-MS/MS QTOF) 
as well described previously (34). 
 
Animals 
Male C57BL6 mice (7-8 week of age) were purchased from Charles River (Senneville, 
Montreal) and housed in individual cages at 24 ± 1 °C under a 12-h light/dark cycle with 
free access to a standard laboratory chow diet (2018 Teklad Global, containing 18.6% 
protein, 3.5% carbohydrates and 6.2% fat for 3.1 kcal/g, Harlan Laboratories, 
Indianapolis, IN). Experiments were performed during the light phase of cycle. Animal 
experiments were conducted according to the Canadian Council on Animal Care 
guidelines for the care and use of experimental animals and were approved by the 
Institutional Animal Care Committee of the Sainte-Justine UHC Research Center. 
Several batches of animals, each with 5-6 animals/group, were used to complete all 
experiments. 
 
Induction of DSS-induced colitis and collection of biological specimens 
After a one-week adaptation under standard conditions, the mice were randomly divided 
into six groups. All mice received water and were fed ad libitum throughout the whole 
experimental period (20 days) with the chow diet (Controls, CTL). Colitis was induced 
by adding 2.5% (w/v) DSS (average molecular weight 36 000-50 000, MP Biomedicals) 
in the drinking water for 10 days (Supplementary Figure S1). The conditions of DSS 
administration (2.5% for 10 days) were chosen to induce a mild-to-moderate colitis that 
could be more amenable to nutritional prevention or therapy (35, 36).  
In addition to the noncolitis CTL group, the five DSS colitis groups were distributed as 
follows: DSS colitis group received only the vehicle (water used to administer DAPP) by 
oral gavage; the preventive groups were orally treated by gavage with 200 mg/kg/day 
DAPP (DAPP-200/DSS) or 400 mg/kg/day DAPP (DAPP-400/DSS) starting 10 days 
before colitis induction and maintained post induction; and the therapeutic groups were 
orally treated by gavage with 200 mg/kg/day DAPP (DSS/DAPP-200) or 400 mg/kg/day 
DAPP (DSS/DAPP-400) starting with colitis induction for 10 days. Fresh DAPP solution 
was provided daily and the DSS solution was replaced every day. Similarly, body weight 
and food/water intake were measured on a daily basis. Thereafter, mice were fasted 






puncture and plasma was separated by centrifugation at 3000 x g for 20 min at 4 °C. The 
peritoneal cavity was then opened and the colon from the ileocecal junction to the rectum 
was rapidly excised, measured (length and weight), cut open lengthwise and the content 
removed with saline for the analysis of mucosa-associated microbiota, flash-frozen, and 
stored at −80°C for experiments. In several experiments, prior to freezing, cross-sections 
of distal colon were fixed in 10% neutral buffered formalin for histological examination. 
 
Disease activity index 
The severity of DSS-induced colitis was evaluated using the disease activity index (DAI), 
which combines scores for the mean values of body weight loss as well as stool 
consistency and occult blood (37). The body weight loss was determined by calculating 
the percentage of weight change from the start of DSS administration until sacrifice (0 = 
none; 1 = 1-5%; 2 = 5-10%; 3 = 10-20% and 4 = >20%). The stool consistency and 
occult blood scores were determined using the scoring systems (0 = normal; 1 = 
moist/sticky stool; 2 = soft stool; 3 = soft stool with mild diarrhea; 4 = diarrhea only) and 
(0 = no blood; 1 = minimal blood in stool; 2 = mild blood in stool; 3 = evidence blood in 
stool and 4 = only blood), respectively. 
 
Histological analyses  
As mentioned, at the end of the experimental period, a specimen of the colon was fixed in 
10% neutral buffered formalin, dehydrated in gradient ethanol series and embedded in 
paraffin. For histological evaluation, 5 µm-thick tissue sections were stained with 
hematoxylin phloxine saffron and examined under an optic microscope (ZEISS IMAGER 
A1 microscope) by a pathologist who was unaware of the experimental protocol. The 
pictures were taken using a digital camera at 10X and 20X resolution. To quantitatively 
compare the severity of lesions between mouse treatments, tissues were assessed for 
injury and inflammation using a semi-quantitative scoring system (38). Sections were 
scored as focal (<10% of specimen), multifocal (10–50% of specimen), or diffuse (>50% 
of specimen) for mucosa, submucosa and muscularis. The muscularis damage was 
evaluated in a blind manner by estimating the amount of myocytes, vacuoles, necrosis 
and infiltration of cells (maximum score = 9). The submucosa damage was evaluated by 
estimating the infiltration of mononuclear, polymorphonuclear and eosinophilic cells 
(maximum score = 3). The characterization of the damage of the surface mucosal 
epithelium was evaluated by erosion, necrosis, exulceration, and loss of the mucus layer 
(maximum score = 12). All scores on the individual parameters together could results in a 
total score ranging from 0 to 24. 
 
Myeloperoxidase activity assay 
Tissue samples from distal colon were used to determine myeloperoxidase (MPO) 
activity. Tissue homogenates were centrifuged at 5000 x g at 4°C for 15 min and MPO 
activity in the supernatant was analyzed by ELISA (Hycult biotech, Uden, the 
Netherlands). All the samples of the six mouse groups were analyzed on the same plate at 
450 nm. 
 






Estimation of lipid peroxidation was assessed by measuring the content of 
malondialdehyde (MDA) in tissue samples of the distal colon by HPLC as described 
previously (34).  
 
Endogenous antioxidant enzyme activities 
Total superoxide dismutase (SOD) activity was determined as described previously. For 
glutathione peroxidase (GPx) activity, aliquots of distal colon were added to a PBS buffer 
containing 10 mM GSH, 0.1 U G-Red and 2 mM NADPH with 1.5% H2O2 to initiate the 
reaction as described previously (39). 
 
Prostaglandin E2 determination 
Tissue samples from the distal colon (fixed amount 10 mg) were homogenized in 1 mL of 
0.1M phosphate pH 7.4 containing 1 mM EDTA and centrifuged at 5 000 x g at 4oC for 
15 min. A dilution of sample supernatant 1:3000 was assayed. Prostaglandin E2 (PGE2) 
levels were measured by ELISA (Arbor Assay, Michigan, USA). The intensity of the 
generated color was detected at the 450 nm wavelengths using a microtiter plate reader 
(EnVision Multilabel Plate Readers, PerkinElmer). Concentrations were estimated from 
the absorbance of the calculated standard curve. 
 
RNA isolation, reverse transcription and quantitative PCR analyses 
Total RNA was isolated from distal colonic tissues from the 6 mouse groups using 
QIAzol Lysis Reagent (QIAGEN, Maryland, USA) according to the manufacturer’s 
instructions. Precipitated total RNA was then resuspended in RNAse-free sterile water 
and further purified through sequential precipitation with lithium chloride and sodium 
acetate to prevent the inhibitory effect of DSS on polymerase enzymatic activity (40). 
The RNA quality was assessed by agarose gel electrophoresis, and cDNAs were 
synthesized from 400 ng of RNA using the Reverse Transcriptase Kit (Invitrogen, 
Carlsbad, CA). Gene expression was analysed by quantitative RT-PCR (qRT-PCR) 
according to our previous studies (41, 42).  
 
Immunoblot analysis  
Tissue samples from the distal colon were homogenized in cold PBS buffer with 4 mM 
EDTA and 10 µL protease inhibitor cocktail (leupeptin, pepstatin, PMSF, ALV and 
BHT). The Bradford assay (Bio-Rad, Mississauga, ON) was used to determine the 
protein concentration. Proteins were denatured in sample buffer containing SDS and ß-
mercaptoethanol, separated on a 7.5 % SDS-PAGE and electroblotted onto Hybond 
nitrocellulose membranes (Amersham, Baie D’Urfé, QC).(41) Specific binding sites of 
the membranes were blocked using defatted milk proteins followed by the addition of one 
of the following primary antibodies: 1/1000 polyclonal anti-COX-2 (70 kDa, Novus, 
Oakville, ON); 1/10000 polyclonal anti-NF-kB (65 kDa, Santa Cruz Biotechnology, 
Santa Cruz, CA); 1/5000 polyclonal anti-IkB (39 kDa, Cell Signaling, Beverly MA); 
1/5000 polyclonal anti- tumor necrosis factor (TNF)-a (26 kDa, R&D, Canada); 1/5000 
monoclonal anti-interleukin (IL)-6 (25 kDa, R&D, Canada), 1/1000 polyclonal anti-Nrf2 
(68 kDa, Abcam, MA, USA); 1/1000 polyclonal anti-PGC-1a (92 kDa, Abcam, MA, 
USA); 1/1000 polyclonal anti-OGG1 (39 kDa, Novus Biologicals); 1/1000 monoclonal 






kDa, Abcam); 1/1000 peroxisome proliferator-activated receptor (PPAR)γ (55 kDa, Santa 
Cruz); 1/40000 monoclonal anti-b-actin (42 kDa, Sigma, MO, USA). 
 
The relative amount of primary antibody was detected with species-specific horseradish 
peroxidase-conjugated secondary antibody (Jackson Laboratory, Bar Harbor, Maine). 
The β-actin protein expression was determined to confirm equal loading. Molecular size 
markers (Fermentas, Glen Burie, Maryland) were simultaneously loaded on gels. Blots 
were developed and the protein mass was quantitated by densitometry using an HP 
Scanjet scanner equipped with a transparency adapter and the UN-SCAN-IT gel 6.1 
software.  
 
Measurement of ADP and ATP levels 
ADP and ATP contents were measured using an ADP/ATP bioluminescent assay kit from 
BioAssay Systems (Hayward, CA, USA) as described previously (43, 44). Values for 
mitochondria were then normalized with regard to the protein content. 
 
Microarray screening and data analysis 
Transcripts were assayed by microarray (45) and the probes were generated from RNA 
isolated from 4 mouse groups (CTL, DSS, DAPP-200/DSS, and DSS/DAPP-400, n=3 for 
each group). The 12 samples were processed at the microarray platform of the Princess 
Margaret Genomics Centre (Toronto, ON). Illumina mouse whole genome WG-6 
expression beadchips were screened, analyzed and quantile normalized via the Princess 
Margaret Genomics Centre (data are accessible through Gene Expression Omnibus 
(GEO)**** and are all MIAME compliant). For each gene, samples bearing a coefficient 
of variation larger than 10%  (representing less than 1% of all samples) were not 
considered in the statistical analysis and a Kruskal-Wallis analysis (P<0.05) was used to 
identify genes expressed differentially (using TMEV 4.9 software).  
 
Ingenuity Pathway Analysis (IPA) analysis 
Functional analyses were performed using IPA (Ingenuity Systems Inc., Redwood City, 
CA, USA) to identify functional pathway enrichment (45) involved in the preventive and 
therapeutic effects of polyphenols in apple peel on intestinal inflammation. Each gene 
identifier was mapped to its corresponding gene object in the Ingenuity Knowledge Base. 
IPA used Fisher’s exact test to calculate a p-value, which gave the likelihood that the set 
of genes in this pathway could be explained by chance alone. 
 
16S rRNA gene amplicon sequencing using the Illumina MiSeq platform 
A total of 36 gut mucosal samples consisting of pooled material of two or three mice 
from the same group were kept at -80°C until being processed. Bacterial DNA of these 
samples was extracted using a mechanical lysis of bacterial cells (Bead-beater) combined 
with silica-based column purification kit as directed by the manufacturer (ZR Fecal DNA 
Minprep; Zymo Research, USA). Total extracted DNA was quantified with a Qubit (Life 
Technologies, USA) and DNA purity was assessed using a ND-1000 Nanodrop 
(Nanodrop Technologies, USA). The 16S rRNA sequencing was performed according to 
a previously described method (46). The V3-V4 region of the 16S rDNA gene was 






Bakt_805R (5'-GACTACHVGGGTATCTAATCC-3') adapted to incorporate the 
transposon-based Illumina Nextera adapters (Illumina, USA) and a sample barcode 
sequence allowing multiplexed paired-end sequencing. PCR mixtures contained 1X Q5 
buffer (NEB), 1X Q5 Enhancer (NEB), 200 µM dNTP (VWR International, Canada), 0.2 
µM of forward and reverse primer (Integrated DNA Technologies, USA), 1 U of Q5 
(NEB) and 1 µL of template DNA in a 50 µL reaction. The PCR cycling conditions 
consisted of an initial denaturation of 30 s at 98°C, followed by a first set of 15 cycles 
(98°C for 10 s, 55°C for 30 s and 72°C for 30 s), then by a second step of 15 cycles 
(98°C for 10 s, 65°C for 30 s and 72°C for 30 s) and final elongation of 2 min at 72°C 
before cooling to 4°C forever. PCR products were purified using 35 µL of magnetic 
beads (AxyPrep Mag PCR Clean up kit; Axygen Biosciences, USA) per 50 µL PCR 
reaction. Amplifications were controlled on a Bioanalyzer 2100 using DNA 7500 chips 
(Agilent Technologies, USA). Samples were pooled at an equimolar ratio, the pool was 
repurified as described before and checked for quality on a Bioanalyzer 2100 using a 
DNA high sensitivity chip. The pool was quantified using picogreen (Life Technologies, 
USA) and loaded on a MiSeq system (Illumina, USA). High-throughput sequencing was 
performed at the IBIS (Institut de Biologie Intégrative et des Systèmes - Université 
Laval). The raw sequencing data have been deposited in the NCBI Sequence Read 
Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra/) under the study accession number 
GSE71920. 
 
Bioinformatics of 16S rRNA gene amplicons 
After demultiplexing by the MiSeq platform, raw sequence data obtained from the 40 
sequenced samples were processed using the QIIME software package (version 1.9.0) 
(47). Firstly, paired-end reads obtained for each sample were joined on the overlapping 
ends, then resulting sequences were filtered to remove low read quality score (phred 
˂25). Forward and reverse primers were trimmed from the filtered sequences; reads with 
at least one reverse primer mismatch or where the reverse primer was not found were 
discarded. USEARCH 61 (version 6.1.544) (48) was used to check and filter chimeras 
from the dataset. Out of a total of 40 original samples, two samples were removed from 
the dataset because of too low read count. After those filtering steps, we characterized a 
total of 602 836 sequences for the 38 remaining samples with an average of 15 864 ± 
4459 reads per sample. Final amplicon mean length varied between 441-465 bp for all 
samples. 
16S rRNA sequences that successfully passed the pre-processing steps and presenting 
≥97% nucleotide sequence identity were binned into OTUs (Operational Taxonomic 
Units) using USEARCH 61 (version 6.1.544) (48) with an open-reference methodology. 
Reads that did not hit the Greengenes reference database (August 2013 release) (49) 
during the closed-reference step were subsequently clustered de novo at 97% identity 
threshold. Taxonomic assignment of representative OTU sequence form each cluster was 
then performed against the Greengenes reference database using the naive Bayesian RDP 
classifier at default parameters (50). Singleton OTUs (cluster with a unique sequence 
occurring only once among all reads) and OTUs with a number of sequences ˂0.005% of 
total number of sequences (51) were discarded at this step. A subsampling depth of 6412 
reads (smallest amount of sequences originally found among our 38 metagenomic 






that were unclassified at the genus level with the Greengenes database were further 
investigated with the RDP classifier against the RDP database (version September 17, 
2014) (52) using a minimum bootstrap cut-off of 50% (53). 
 
Statistical analysis 
All values are expressed as mean ± SEM. Data were analyzed by using a one-way 
analysis variance and the two-tailed Student’s t test using the Prism 5.01 (GraphPad 
Software) and the differences between the means were assessed post-hoc using Tukey’s 
test. Statistical significance was defined as P<0.05. 
The software PC-ORD (version 6; MjM Software, USA) was used to perform a principal 
coordinates analysis (PCoA) in order to illustrate differences between taxonomic profiles 
of metagenomic samples at the genus level. This ordination method combined with Bray-
Curtis distance measure is well suited for species abundance data avoiding the 
assumption of linear relationship between variables. STAMP (Statistical Analysis of 
Metagenomic Profiles, version 2.0.9; Parks & Beiko, 2014) was employed to perform 
two-way comparisons of taxonomic distributions (at the genus level) between 
metagenomic samples (e.g. CTL vs DSS-treated), using the White's non-parametric t-test 
associated with the bootstrap method for calculating confidence intervals (nominal 
coverage of 95%). A Storey FDR approach was used to indicate the percentages of false 
positives (reported by q-values) that should be expected among all significant taxonomic 
units illustrated on bar plots. In order to visualize the relationships between OTUs and 
samples, a heatmap was constructed with STAMP using the Kruskal-Wallis H-test 
combined with the Tukey-Kramer test as post-hoc analysis. Multiple test correction for 
the heatmap analysis was performed with the Storey FDR approach. For all analyses 
performed within STAMP, only specific families or genera of interest were considered 








Profile of phenolic compounds of DAPP  
A reversed phase LC-MS method has been developed in order to separate and identify 
masses and chemical structures of polyphenolic compounds contained in the DAPP 
extract. Flavonoids figured among the major polyphenol classes: they were identified on 
the basis of their common structure consisting of two aromatic rings bound together by 
three carbon atoms that form an oxygenated heterocycle. Representative extracted ion 
chromatograms of identified DAPP polyphenolic compounds, using accurate mass 
measurement, are shown in Supplementary Figure S2. The DAPP was essentially 
constituted of hydroxycinnamic acids (Supplementary Figure S2A), dihydrochalcones 
(Supplementary Figure S2B), flavan-3-ols (Supplementary Figure S2C), and flavonols 
(Supplementary Figure S2D). The hydroxycinnamic acids were composed of isomers of 
coumaric acids, p-coumaroylquinic acids and caffeoylquinic acids while we found 
phloretin and phloridzin as dihydrochalcones. The accurate mass measurement revealed 
that the flavan-3-ol subclass was constituted of (+)-catechin, (-)-epicatechin, (+)-catechin 
3-O-gallate, and (+)-catechin 3-O-glucose (Table 1). Noteworthy, in the DAPP extract, 
flavonols constituted the dominant subclass of flavonoids and were present as a mixture 
of aglycone and glycosylated quercetin (Supplementary Figure S2D and Table 1).  
 
Effects of DAPP on the severity of DSS-induced colitis in mice 
Mice exposed to oral administration of 2.5% DSS over 10 days was characterized by 
sustained weight loss (Figure 1A), abnormal stool consistency (Figure 1B) and bloody 
diarrhea (Figure 1C), which presented a significant increase in DAI (Figure 1D). To 
assess the preventive and therapeutic effects of polyphenols, the mice were treated with 
DAPP before or during induction and development of colitis at two different doses (200 
and 400 mg/kg/day). All DAPP animal groups exhibited significantly reduced DAI scores 
compared with the DSS colitis group without the DAPP treatment (Figure 1D). As the 
colon length is inversely correlated with the severity of colitis and is considered to be an 
indirect marker of inflammation, we examined colon shrinking. While the DSS group had 
significantly shorter colons relatively to the control group (Figures 1E and 1F), the 
preventive (200 mg) and the therapeutic 400 mg/kg/day doses of DAPP displayed the 
most significantly beneficial effect on colon shortening reduction compared with the 
group on DSS alone (Figures 1E and 1F).  
No histopathological changes were observed in colons from the control group, (Figure 
2A). In contrast, the histopathological examination of the distal colon of mice treated 
with DSS showed mucosal ulceration, which was marked by an increased thickness of the 
muscle layer, loss of crypt structure, multifocal inflammatory cell infiltration into 
submucosal, severe denudation of the surface epithelium (erosion) and mucodepletion of 
glands (Figure 2B). Except for the group with the DAPP-400/DSS, DAPP significantly 
decreased the microscopic inflammation score for DSS-induced colitis in the other 
groups (Figure 2G). For example, mice pretreated with 200 mg/kg/day of DAPP showed 
less structural damage and inflammatory cell infiltration without a significant effect on 
muscle layer thickness compared to the DSS group without DAPP treatment (Figure 2D). 
Moreover, the epithelium in various areas remained intact and the mucin layer was 






process. Noteworthy, the high 400 mg/kg/day therapeutic DAPP dose resulted in near-
normal colonic histology (Figure 2E) whereas the mice treated with the high 400 
mg/kg/day preventive DAPP dose still showed several severe ulcers (Figure 2F). The 
colonic lesions were evaluated by a semi-quantitative scoring system that assesses the 
muscularis, submucosa and surface mucosal epithelium damages. Representation of total 
microscopic damage score demonstrated that preventive and therapeutic dose of 200 
mg/kg/day of DAPP decreased colonic lesions (Figure 2G). However, therapeutic dose of 
400 mg/kg/day of DAPP had the lowest total microscopic damage score (Figure 2G). 
 
Effects of DAPP on colonic leukocyte involvement in DSS-induced colitis in mice   
The colonic MPO activity, as a marker of inflammatory cell infiltration, was significantly 
increased in the colitis group (25-fold) compared to control mice (Figure 2H). All DAPP 
groups showed a reduction in the degree of polymorphonuclear neutrophil infiltration. 
The mice treated with the preventive 200 mg/kg/day dose of DAPP showed only a trend 
of decrease in MPO activity in distal colonic tissue 
 
Effects of DAPP on Lipid Peroxidation in the distal colon of DSS-induced colitis mice 
Compared to the control group, DSS significantly increased lipid peroxidation in the 
distal colon (Figure 3A). When mice were pretreated with 200 or 400 mg/kg/day DAPP, 
DSS-induced lipid peroxidation was prevented. On the other hand, only the highest 
therapeutic dose of DAPP (400 mg/kg/day) was able to totally counteract lipid 
peroxidation occurrence.  
 
Mechanisms for the action of DAPP on oxidative stress 
As failure of antioxidant defense may favor the induction of OxS, we examined 
endogenous antioxidant enzymes and found that the treatment with DSS alone caused a 
significant augmentation in the SOD activity compared to the CTL group (Figure 3B). 
However, the preventive (200 mg/kg/day) or therapeutic dose of 400 mg/kg/day of DAPP 
was the most efficient conditions for maintaining SOD activity quite comparable to that 
of the CTL group (Figure 3B). Only a slight decrease was noted in the other DAPP-
400/DSS group. Under these conditions, GPx activity was down regulated by DSS 
(Figure 3C), and restored by the same preventive and therapeutic doses. 
We examined the transcription factor Nrf2 that regulates antioxidant genes expression. 
While DSS-induced colitis down regulated the gene (50%) and protein (30%) expression 
of Nrf2 (Figures 3D and 3E), and the preventive DAPP dose of 200 mg/kg/day was 
capable of inhibiting the decrease of Nrf2 gene expression in DSS-treated mice (Figure 
3D). Apart from the therapeutic dose of 200 mg/kg/day, the other groups (DAPP-
400/DSS and DSS/DAPP-400) showed a particularly favorable influence on protein 
expression of Nrf2 (Figure 3E).  
 
Effects of DAPP on inflammatory markers in the distal colon of DSS-induced colitis 
mice 
As Cyclooxygenase-2 (COX-2) produce excessive inflammatory mediators, which are 
detrimental to the integrity of the colon and contribute to the development of intestinal 
damage, we evaluated its protein expressions. As shown in Figure 4A, the COX-2 protein 






DAPP treatments were able to lessen the exaggerated induction of COX-2 protein 
expression noted in DSS mice. To confirm these findings, we assessed the prostaglandin 
E2 (PGE2) that is a major downstream mediator of COX-2. PGE2 concentrations were 
significantly decreased by preventive and therapeutic DAPP treatments in DSS mice 
(Figure 4B). Therefore, DAPP is able to down regulate the COX-2-PGE2 pathway that is 
of high pharmacological interest for IBD.  
To further evidence the anti-inflammatory capacity of DAPP, we assessed its influence 
on cytokines expressions (Figure 5). While the DSS resulted in severe inflammatory 
response as indicated by strong increases in colonic levels of the proinflammatory TNF-α 
and IL6 as compared to the CTL group, DAPP strongly antagonized this inflammation 
magnitude given the marked drop of the colonic mRNA content and protein expression of 
these cytokines. Interestingly, the TNF-α gene expression was decreased only in the 
group of mice that received 400 mg/kg/day of DAPP (Figure 5A). 
 
Mechanisms for the action of DAPP on transcription factors 
As the ubiquitous eukaryotic transcription factor NF-κB is mainly responsible for 
regulating the induction of pro-inflammatory cytokines, we examined the potential of 
DAPP to inhibit its activation in mouse colonic samples inflamed with DSS (Figures 5C). 
In fact, treatment with DAPP caused a significant inhibition of NF-κB/IκB ratio (Figure 
5F). Noteworthy, the effect was more pronounced with the 200 mg/kg/day and 
therapeutic 400 mg/kg/day doses (Figure 5F). 
We also evaluated the modulation of two crucial transcription factors: peroxisome 
proliferator-activated receptor γ Coactivator-1α (PGC-1α) and peroxisome proliferator-
activated receptor (PPAR)γ. The levels of PGC-1α (Figures 6A and 6B) and PPARγ 
(Figures 6C and 6D) were down regulated in the DSS group comparatively to the CTL 
group. Whereas the therapeutic 200 mg/kg/day dose of DAPP was inefficient in 
enhancing PGC-1α mRNA and protein levels in DSS-treated mice, a significant trend of 
increase was noted in the other groups. With regard to PPARγ, an increase was noted in 
all the groups except for the preventive DAPP-400/DSS group. 
 
Effect of DAPP on mitochondrial functions in mice with DSS-induced colitis 
As the ADP/ATP ratio is generally considered a key parameter in mitochondrial energy 
metabolism and respiration, we established its status (Figure 7A) in purified mitochondria 
from the distal colons. The ADP/ATP ratio for the DSS group increased 4-fold compared 
to the control group, but the used therapeutic dose of 400 mg/kg/day reduced 
significantly this ADP/ATP ratio induction.   
AIF is located in the inter-membrane space of mitochondria and is involved in initiating a 
caspase-independent pathway of apoptosis by causing DNA fragmentation and chromatin 
condensation. Furthermore, when colonic cell death is triggered by an apoptotic stimulus 
like DSS, cytochrome (Cyt) C is released into the cytosol and contributes to caspase-
dependent pathway of apoptosis. Western blot analysis revealed an increase in the AIF 
and Cyt C protein masse in the mitochondrial preparation following DSS-induced colitis 
(Figures 7B and 7C). However, the therapeutic and preventive dose of 400 mg/kg/day 
was able to restore their normal levels. 
The base excision repair pathway is primarily responsible for removing 8-OHdG from 






DNA glycosylase (OGG1), an enzyme that recognizes and hydrolyses the aberrant base 
from the DNA backbone. As illustrated in Figure 7D, the DSS treatment resulted in a 
significant reduction in OGG1 protein mass as compared with CTL group. However, the 
therapeutic and preventive dose of 400 mg/kg/day prevented the decline in OGG1 
expression. 
 
Group comparisons using a score summation index 
To compare the outcomes under the different conditions, we employed a score 
summation index (Supplementary Table S1). The total score was calculated by summing 
the various effects of DAPP in the different animal groups. As higher scores indicate 
greater improvements of the DSS group in response to polyphenol administration, we 
could identify two distinctive groups that exhibit the best outcomes, i.e. the preventive 
group with 200 mg/kg/day and the therapeutic group with 400 mg/kg/day. Therefore, we 
selected these two groups to conduct a microarray analysis of colonic gene expression 
and to examine the effect of the polyphenol treatment on the modulation of the gut 
microbiota. 
 
Functional pathways involved in the effect of DAPP in mice with DSS-induced colitis. 
To further determine the effect of DAPP in mice with DSS-induced colitis, we 
established colonic gene expression profiles for each group (CTL, DSS, DAPP-200/DSS, 
and DSS/DAPP-400, n=3 for each group) using Illumina mouse whole genome WG-6 
expression beadchips. Statistical analyses revealed that 2152 genes were differentially 
expressed between each group (Supplementary Table S2). Significantly differentially 
expressed genes were subjected to IPA software. Comparative analysis of the cellular, 
molecular, physiological and metabolic functions was performed and classified according 
to statistical significance in the variation of the expression of genes in DSS/DAPP-400 
and DAPP-200/DSS. Supplementary Tables S3 and S4 list 86 and 89 categories for 
DSS/DAPP-400 and DAPP-200/DSS, respectively, which were sorted according to their 
statistical significance as the negative logarithm of P-values calculated by IPA. Plotting 
the negative logarithm of p-values calculated by IPA for each of the functional categories 
found in the DSS/DAPP-400 group against the negative logarithm of P-values of the 
corresponding categories found in the DAPP-200/DSS group allows visualization of 
functions that are most relevant to each treatment. In Figure 8, we plotted the most 
significant 25 functional categories in each group, and found that 14 of them were altered 
in both groups. Among the shared canonical pathways we identified “IL6 signalling”, 
“Atherosclerosis signalling”, “LXR/RXR activation”, “Acute phase response signalling” 
and “IL10 signalling”, demonstrating that the DAPP treatment was able to modulate 
several inflammatory pathways. Interestingly, our results also evidenced that the 
preventive rather than the therapeutic treatment exclusively regulated some biological 
functions. For instance, preventive effects modulated “PPAR signalling”, “Fc epsilon RI 
signalling” and “Dendritic maturation” while “Gap junction signalling”, “FcγRIIB 
signalling in B lymphocytes” and “Epithelial adherents junctions signalling” were 
modulated by therapeutic treatment, suggesting differential beneficial effects depending 
on the treatment period.  






In order to assess the effect of DAPP on gut dysbiosis induced by DSS, we performed a 
16S rRNA metagenomic analysis of 38 gut mucosal collections from the CTL, DSS-
induced colitis (DSS), preventive (DAPP+DSS) and therapeutic (DSS+DAPP) groups. 
As no significant difference in gut bacterial composition was found between 
metagenomic samples from mice treated with different doses (200 and 400 mg/kg/day) of 
DAPP, only therapeutic DAPP administration at the 400 mg/kg/day dose was considered 
for further metagenomic analyses.  
The PCoA plot (Figure 9A) indicates the correlation between bacterial communities and 
the different treatments administered in mice. A clear shift from the CTL to all the treated 
animals groups (DSS, DSS+DAPP, DAPP+DSS) occurred along the first (and the most 
influential) component. The genera Parabacteroides, Ruminococcus, and more 
specifically Barnesiella and Anaerostipes, were strongly associated with the healthy state, 
while Akkermansia and Mucispirillum genera were more abundant in the metagenomes of 
treated mice; in particular, the families Peptostreptococcaceae and Enterobacteriaceae 
were significantly correlated with treated animal samples. In addition, the Figure 9B 
illustrates that those two bacterial families were absent from the control metagenomic 
sample, and consequently, only represented in the groups where DSS was administered; 
conversely, the genus Anaerostipes was only found in the CTL group. The relative 
abundance of Akkermansia and Mucispirillum was significantly more important in the 
metagenomes of treated animals than in the CTL group. The proximity between the CTL 
and the DSS+DAPP treated mice in the PCoA plot is slightly greater than the one 
observed between the DSS and CTL groups, likely indicating a more pronounced 
bacterial profile similarity between the therapeutic and healthy metagenomes. 
Associations between gut bacterial composition and treated mice groups were further 
investigated by pairwise comparisons of gut bacterial profiles with respect to treatment 
(Figure 9B). Peptostreptococcaceae and Enterobacteriaceae families were clearly 
overrepresented in the DSS metagenome, whereas the mean proportion of Barnesiella 
was significantly higher in the CTR group, along with Parabacteroides and 
Ruminococcus. Sequences assigned to Peptostreptococcaceae and Enterobacteriaceae 
were more abundant in the metagenomes of DSS+DAPP and DAPP+DSS groups in 
comparison with the CTLs, but to a less extent than in the DSS-treated mice (Figure 10). 
Interestingly, reads classified as Peptostreptococcaceae was less numerous in the 
metagenome of therapeutics DAPP-treated mice than in the DAPP+DSS mice when 
compared to the CTR group. The genus Mucispirillum was overrepresented in both 
DSS+DAPP and DAPP+DSS metagenomes compared to the CTLs, while the mean 
proportion of sequences attributed to Akkermansia was higher in the metagenome of the 







IBD constitute a major health problem in the Western world. As no cure exists and no 
definitive therapies are available for this chronic inflammatory disorder, it becomes 
urgent and crucial to develop novel strategies with high efficacy. Multiple scientific 
groups studying functional nutrients have identified polyphenolic compounds among 
complementary and alternative medicines. However, the full spectrum of biological 
activities and the mechanisms of actions have rarely been reported. Therefore, in this 
study, we address the following issues: Does oral administration of DAPP protect against 
sustained oxidative stress and inflammation, two characteristic features of IBD? Is DAPP 
efficient in preserving mitochondrial bioenergetics and functions known to be affected in 
IBD? Can DAPP trigger central transcription factors that are master regulators of 
antioxidant, anti-inflammatory and mitochondrial cytoprotective mechanisms? What is 
the transcriptomic signature that can be disclosed by microarray analysis of colonic 
specimens in response to DAPP treatment on a mouse model of induced colitis? What are 
the microbiota changes elicited by DSS-induced intestinal injury and are they restored by 
DAPP administration? Is DAPP beneficial for prevention and management?  
 
We found that DAPP treatment showed an improvement of weight loss, diarrhea and 
bloody stools at a macroscopic level, but it also improved the histology at a microscopic 
level given the reduction of inflammatory cell invasion into colonic tissue. Our findings 
also support this alleviation of inflammation in response to DAPP supplementation as 
noted by the reduced expression of pro-inflammatory cytokines (TNF-α) and eicosanoids 
(PGE2). Consistently, DSS-mediated oxidative stress and mitochondrial dysfunctions 
were ameliorated given the substantial fall in MDA and the ADP/ATP ratio along with 
the strengthening of antioxidant defense. The limited oxidative and inflammatory 
magnitude, displayed following DAPP administration, may be due to the regulation of 
transcription factors and nuclear receptors as well as to the modifications of the 
microbiota composition and transcript profiling. In this context, we also observed a slight 
decrease in the relative abundance of Peptostreptococcaceae and Enterobacteriaceae in 
DAPP-treated mice compared to DSS-induced colitis group, suggesting that polyphenolic 
compounds exert an antioxidant effect on the mucosal inflammatory milieu. Our results 
highlight the potential of using DAPP to prevent and treat IBD via numerous 
mechanisms.  
 
In our study, special attention was given to the analysis of the composition of 
polyphenols as their concentration and antioxidant activity may vary depending on food 
processing and seasonal differences. Using the high-resolution of UPLC-ESI-MS/MS 
QTOF, we evidenced the presence of flavonols (aglycone and glycosylated quercetin), 
flavan-3-ols [(+)-catechin and (-)-epicatechin], dihydrochalcones (phloretin and 
phloridzin) and hydroxycinnamic acids, which represent the major flavonoid subclasses 
that exhibited anti-inflammatory and antioxidant activities in our previous studies (34).  
 
Noteworthy, not only we have used in the present study apple peels that constitute a good 
source of phenolic compounds (30, 32), but the concentrations of phenolic extract 






of 100 g of fresh apple widely consumable by humans (~ 357 mg/100 g fresh apple) 
(54, 55). In addition, the pheno l i c  doses used in this study in mice are easily 
attainable in humans by applying the US Food and Drug Administration’s guidelines 
to establish the human equivalent dose based on body surface area (56). We also 
doubled the DAPP dose to 400 mg to examine whether large quantities of polyphenols 
can have more desirable outcomes especially in the therapeutic mode. 
 
The main reason for the administration of the two concentrations of polyphenols (200 and 
400 mg/kg/day) is not to examine the dose response, but rather to understand how mice 
with DSS-induced experimental UC respond to physiological and supraphysiological 
doses. We reasoned that the physiological concentration (200 mg/kg/day) may better suit 
preventive action while the 400 mg/kg/day dose may work better in therapeutic 
intervention given the numerous and serious implemented health abnormalities to 
counteract. According to our results, this hypothesis proved true. In this context, it is 
important to mention that our data converge with previous studies. For example, 
flavonoids such as epigallocatechin gallate (EGCG), a powerful natural anti-
inflammatory substance, inhibited acetic acid-induced colitis in rats at a dose of 50 
mg/kg/day (57), but higher doses exacerbated inflammation (58). In this study, the 
authors concluded: ‘’ It may be prudent for individuals with IBD to avoid excessive doses 
of supplemental EGCG for colitis management until further evidence of its safety and 
efficacy in human intervention studies.’’ Similar to EGCG, green tea polyphenols at 
doses <0.5% inhibited DSS-induced colitis, while doses of 0.5% to 1% fortified colitis 
symptoms and mortality (59-61). Another example is represented by genistein that a dose 
of 20 mg/kg reduced survival relative to the non-treated DSS-control group whereas 
lower concentrations (2 and 10 mg/kg) were more beneficial (62). 
 
Evaluation of the preventive and therapeutic effects of DAPP showed a significant 
improvement of the DSS-induced clinical manifestations, as evidenced by the alleviation 
of body weight loss, diarrhea and fecal bleeding. In addition, supplementation of DAPP 
ameliorated colon shortening and colonic histological damages in the DSS-induced colitis 
mouse model. It also lessened neutrophils influx into the colonic tissue since the MPO 
activity was decreased, which evidenced the role of DAPP in restraining the induction of 
neutrophils recruitment. Moreover, DAI scores were markedly lower in the DAPP groups 
than in the DSS group. Taken together, these data demonstrate the preventive and 
therapeutic efficacy of DAPP against colitis development. Interestingly, the maximal 
preventive effect of DAPP was mostly achieved at the dose of 200 mg/kg/day but not 
with curative doses employed in our study. 
 
A large number of experimental and clinical data suggests that chronic intestinal 
inflammation may be the result of a sustained overproduction of pro-inflammatory 
cytokines (63, 64). As inflammatory mediators like TNF-α and IL-6 play critical roles in 
the pathogenesis of murine colitis, we analyzed their expression by qPCR and Western 
blot. Consistent with previous reports (65-70), the levels of these pro-inflammatory 
cytokines in DSS-induced mice were found positively correlated to the severity of colitis 
in the current study. Furthermore, DAPP significantly provided suppressive effects on 






halts the pathological progression of pro-inflammatory cascade. To delineate the 
mechanism of DAPP anti-inflammatory action, we assessed the expression of nuclear 
NF-κB that functions in the transcription regulation of numerous genes (71) and appeared 
remarkably elevated in colonic tissues of animals with colitis (72, 73). Estimation of NF-
κB and its inhibitory molecule IκB (capable of preventing the translocation of NF-κB to 
the nucleus for the transcription activation of pro-inflammatory target genes) showed the 
capacity of DAPP to reverse NF-κB increase and cytoplasmic IκB degradation in mice 
with DSS-induced colitis. In fact, DAPP weakened NF-κB p65 signals while enhancing 
the expression of the inhibitory subunit IκB-α, which led to the decline of the NF-κB/ IκB 
ratio. Our results are in accordance with the anti-inflammatory effects of DAPP in 
intestinal epithelial Caco-2/15 cells (34) and are also consistent with previous reports that 
illustrate the efficiency of apple polyphenols to inhibit NF-κB activation in 
lipopolysaccharide/IFNγ-induced inflammation in human cell lines (74) and HLA-B27 
transgenic rats (75). 
 
Up-regulation of certain proteins such as COX-2 is also implicated in immune 
dysregulation characterizing IBD (76). Its induction results in an excessive inflammatory 
response, which may affect colon mucosa integrity and contributes to the development of 
intestinal damage (77). The anti-inflammatory activity of DAPP was further confirmed 
by measuring colonic COX-2 levels. As highlighted by our findings, DAPP 
supplementation was able to mediate COX-2 down-regulation and to limit the formation 
of its PGE2 product in parallel with the noted TNF-α and IL-6 blocking as well as MPO 
reduction (as an index of the neutrophils’ presence and activation), thereby proving the 
high efficacy in ameliorating the acute colitis stage. The preventive and therapeutic 
benefits of DAPP supplementation are likely to stem from a global anti-inflammatory 
effect probably via the control of NF-κB signal transduction pathway (78).  
 
As largely reported, IBD is initiated and perpetuated by a combination of deregulated 
immune response and imbalance between the production of free radical and antioxidant 
defense (79, 80). Given the close correlation between the activity of free radicals in the 
gut and DAI severity, indicating the significance of oxidative stress in the inflammatory 
process, we have assessed the impact of DAPP on lipid peroxidation that is responsible 
for many of the damaging reactions in the cell by causing membrane leakiness and 
breakdown (81). Our findings clearly support the protective role of DAPP in the 
regulation of oxidative stress since it significantly averted the elevation of MDA. 
Notably, our data also emphasize the indirect antioxidant effect of DAPP through the 
induction of endogenous protective antioxidative SOD and GPx enzymes through 
activation of Nrf2, which orchestrates the transcription of antioxidant genes and up-
regulation of cytoprotective proteins (82). 
 
Structurally abnormal mitochondria have been observed in tissue from patients with gut 
inflammation (83) and in epithelial monolayers treated with prooxidants (44). Although 
there are limited data on the role of mitochondria in colitis, there is a growing interest in 
targeting mitochondria-derived oxidative stress to reduce epithelial barrier dysfunction 
and colitis (84). Our findings show the effectiveness of DAPP to enhance mitochondrial 






protein expression in DSS-treated mice. Furthermore, DAPP was able to counteract the 
DSS-induced drop of OGG1, an enzyme that recognizes and hydrolyzes the aberrant 
nucleic bases from the DNA backbone. Our data are consistent with previous 
investigations showing that polyphenols are able to protect against the loss of 
mitochondrial membrane potential, the increment in lipid peroxidation and the fall in 
cellular ATP induced by indomethacin in Caco-2 cells (85). Mechanistically, this 
mitochondrial regulation by DAPP may be mediated via the increase of PGC-1α that is a 
master modulator of mitochondrial biogenesis and a transcriptional regulator of cellular 
energy processes, including OXPHOS and fatty acid oxidation (86-88). It is tempting to 
speculate that DAPP may have salutary effects via the induction of PGC-1α on 
mitochondrial dysfunctions since quercetin was recently reported to enhance the 
expression of PGC-1α in conjunction with mitochondrial biogenesis and functions (89). 
 
In comparison with the CTL group, DSS treatment induced a reduction in the proportion 
of Parabacteroides and Barnesiella phylotypes, both belonging to the 
Porphyromonadaceae family (Bacteroidales order). Parabacteroides sp. was found to be 
at higher levels in healthy controls than in UC or irritable bowel syndrome patients (90). 
Similarly, higher levels of Barnesiella phylotype were correlated with lower activity 
levels of colitis in IL-deficient mice (91). More interestingly, an increase of the relative 
abundance of Enterobacteriaceae and Peptostreptococceae was also observed in DSS-
induced colitis. The cytotoxic effects of DSS on gut epithelium have been associated with 
an increase of mucus release, intestinal permeability, and acute barrier damage. The loss 
of barrier function allows the translocation of pro-inflammatory microbial products (92, 
93). Then, the induced intestinal inflammation could be responsible for the shift in 
microbial composition observed in mice with DSS treatments, including those with 
DAPP. Lupp et al. found that host-mediated inflammation alone is sufficient to perturb 
the composition of the intestinal microbiota in DSS-induced colitis (94) The host-
mediated inflammation and oxidant-mediated injury also change the environmental 
conditions in the gut (e.g. oxygen availability), which may affect proliferation of some 
phylotypes capable of adapting to these conditions. Specifically, facultative anaerobes 
such as Enterobacteriaceae and Peptostreptococceae may be favored over obligate 
anaerobes such as Porphyromonadaceae (Barnesiella and Parabacteroides) and 
Anaerostipes from increased oxygen availability or resistance to reactive oxygen species 
produced during inflammation (95). 
 
Mucin-degrading bacteria Akkermansia muciniphila and Mucispirillum were found to be 
more numerous in the DSS-treated mice. In agreement with our results, Berry et al. 
observed an increase in Verrucomicrobiaceae (mainly Akkermansia spp.) and 
Deferribacteracae (mainly Mucispirillum spp.) during acute inflammation (95). In DSS-
induced colitis, Mucispirillum and Akkermansia could benefit from the degradation of 
host-derived mucus secretions. Accordingly, mucus composition and secretion are altered 
during inflammation while mucolytic bacteria and mucolytic activity are increased in 
IBD mucosa (95). Interestingly, the higher level of Akkermansia found in the DAPP-
treated animals (compared to the CTL group) under preventive conditions, could be 
interpreted as a prebiotic-like effect of DAPP. This may reflect a partial restoration 






facultative anaerobes. In this context, a substantial rise of Akkermansia has recently been 
associated with improved metabolic state in mice on high-fat/high-sucrose fed in 
response to a polyphenol-rich cranberry extract (46). 
 
In the present study, we also noted a slight decrease of relative abundance of 
Peptostreptococceae and Enterobacteriaceae in DAPP groups (especially in the curative 
mode), suggesting that DAPP phenolic compounds exerted an antioxidant effect on the 
mucosal inflammatory milieu. However, the link between the partial correction of 
bacterial dysbiosis and colitis amelioration in the DSS + DAPP group has not been 
clearly established. The slight shift in bacterial composition compared to DSS group 
could only reflect improved integrity of the intestinal mucosa and decreased 
inflammation. Additional experiments using fecal transplantation of caecal content from 
DAPP-treated animals into DSS mice should be carried out in order to demonstrate that 
colitis improvement observed in DAPP-treated mice represents a cause-effect 
relationship between DAPP and restoration of gut flora.   
 
In conclusion, the present investigation provides in vivo evidence that administration of 
DAPP lessens the intestinal oxidative stress magnitude via the modulation of the NRF2 
that functions as a master switch and regulates a cascade of antioxidant genes containing 
the Antioxidant Response Element (ARE) sequence. The findings also show the 
modulation of intestinal inflammatory response by DAPP through the inhibition of 
neutrophil infiltration and deactivation of the NF-κB signaling pathway. These 
advantageous effects could be attributed, at least partially, to the regulatory role of DAPP 
in mitochondrial functions, messenger RNA phenotype and microbiota that is essential 
for optimal health.  Overall, these positive modifications were associated with significant 
benefits such as reduction of bleeding, improvement in stool consistency, improved 
histological appearance, decreased weight loss, and protection from colon shortening, 
which indicate that polyphenols may represent potent tools for preventing and treating 
IBD. Noteworthy, this preclinical study will help define whether improvement of gut 
dysbiosis by DAPP, in association with the severity of mucosal injury or inflammation 
may constitute a promising treatment option in IBD as suggested previously (96). Finally, 
our study is an appropriate answer to the critically important scientific question seeking 








Apple peel polyphenols may represent efficient functional foods capable of exerting 
beneficial actions on intestinal disorders such as inflammatory bowel diseases. 
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Coumaric acids C9H8O3 C9H7O3 163.0390 163.0395 -3.1 
  Coumaroylquinic 
acids 
C16H18O8 C16H17O8 337.0928 337.0923 1.5 
  Caffeoylquinic acids C16H18O9 C16H17O9 353.0878 353.0872 1.7 
Flavonoids Dihydrochalcone Phloretin C15H14O5 C15H13O5 273.0769 273.0763 2.2 
  Phloridzin C21H24O10 C21H23O10 435.1282 435.1291 -2.1 
 Dihydroflavonol Dihydroquercetin C15H12O7 C15H11O7 303.0520 303.0505 4.9 
  Dihydroquercetin 3-
O-rhamnoside 
C21H22O11 C21H21O11 449.1100 449.1084 3.6 
 Flavanol (+)-Catechin C15H14O6 C15H13O6 289.0709 289.0712 -1.0 
  (-)-Epicatechin 
  (+)-Catechin 3-O-
gallate 
C22H18O10 C22H18O10Na 465.0798* 441.0822 -4.9 
  (+)-Catechin 3-O-
glucose 
C21H24O11 C21H23O11 451.1223 451.1240 -3.8 






  Quercetin 3-O-
arabinoside 
C20H18O11 C20H17O11 433.0721 433.0771 -1.2 
  Quercetin 3-O-
xyloside 
  Quercetin 3-O-
rhamnoside 
C21H20O11 C21H19O11 447.0941 447.0927 3.1 
  Quercetin 3-O-
galactoside 
C21H20O12 C21H19O12 463.0894 463.0876 3.9 
  Quercetin 3-O-
glucoside 
  Quercetin 3-O-
galactoside-7-O-
rhamnoside 
C27H30O16 C27H29O16 609.1471 609.1456 2.5 
  Quercetin 3-O-
rhamnosyl-
galactoside 
  Quercetin 3-O-
rutinoside 
Experimental mass measurement and empirical formula calculation for phenolic acids and flavonoids. A good agreement between the 
theoretical and the experimental m/z values was obtained for all compounds examined (< 5ppm). Separations were performed on an 
ultra-performance liquid chromatography system (UPLC) coupled to a QuanTOF mass spectrometer (MS/MS QTOF) equipped with 
an ESI source (UPLC-ESI-MS/MS QTOF). The UPLC-ESI-MS/MS QTOF system consisting of a Waters-ACQUITY UPLC with an 






Figure 1 Effects of DAPP on macroscopic damage in mice with DSS-induced colitis. 
The severity of the colitis was determined by the disease activity index score 
(D), which combines scores for the body weight change (A) and feces condition 
(stool consistency (B) and fecal bleeding (C). The body weight change was 
determined by calculating the percentage of weight change relative to the 
starting weight before DSS treatment (0 = none; 1 = 1-5%; 2 = 5-10%; 3 = 10-
20% and 4 = >20%). The fecal condition score was determined using two 
parameters: stool consistency (0 = normal; 1 = moist/sticky stool; 2 = soft stool; 
3 = soft stool with mild diarrhea; 4 = diarrhea only) and fecal bleeding (0 = no 
blood; 1 = minimal blood in stool; 2 = mild blood in stool; 3 = evidence blood 
in stool and 4 = only blood). After sacrificing the mice, the colon length was 
measured between the colocecal junction and the rectum (E and F). In addition 
to the noncolitis control group (CTL), the five DSS colitis groups were 
distributed as follows: DSS colitis group received only the vehicle (water used 
to administer DAPP) by oral gavage; the preventive groups were orally treated 
by gavage with 200 mg/kg/day DAPP (DAPP-200/DSS) or 400 mg/kg/day 
DAPP (DAPP-400/DSS) starting 10 days before colitis induction; and the 
therapeutic groups were orally treated by gavage with 200 mg/kg/day DAPP 
(DSS/DAPP-200) or 400 mg/kg/day DAPP  (DSS/DAPP-400) starting with 
colitis induction for 10 days. The results shown are representative of three 
independent experiments with 5 to 6 mice per group. ***P<0.001 vs. CTL 
group; #P<0.05, ##P<0.01, ###P<0.001 vs. DSS group. 
Figure 2 Effects of DAPP on microscopic damage and myeloperoxidase in mice with 
DSS-induced colitis. Histological characterization was assessed by histological 
sections of distal colonic mucosa and tissue samples from distal colon were 
used to determine myeloperoxidase (MPO) concentration (H) from the six 
groups of mice (as described in Supplementary Figure 1) stained with 
hematoxylin phloxine saffron: (A) control group (CTL); (B) colitis group 
(DSS), (C) DSS/DAPP-200, (D) DAPP-200/DSS, (E), DSS/DAPP-400 and (F) 
DAPP-400/DSS. The pictures were taken using a digital camera at 10X 
(pictures B, C and F) or 20X (pictures A, D and E) resolution. Colon sections 
were scored for DSS-induced colonic inflammation and tissue injury (G) as 
described in Materials and Methods. The results shown are representative of 
three independent experiments with 5 to 6 mice per group. ***P<0.001 vs. CTL 
group; ##P<0.01 vs. DSS group. 
Figure 3 Effects of DAPP on oxidative stress markers in mice with DSS-induced 
colitis. Estimation of lipid peroxidation was assessed by measuring 
malondialdehyde (MDA) by HPLC (A). The activity of superoxide dismutase 
(SOD, B), glutathione peroxidase (GPx, C) was then measured. Gene and 
protein expression of the transcription factor Nrf2 (D and E) were determined 
by qPCR and Western blot respectively. The results from the six groups of mice 






independent experiments with 5 to 6 per group. *P<0.05 vs. CTL group; 
#P<0.05 ##P<0.01 ###P<0.001 vs. DSS group. 
Figure 4 Regulatory effects of DAPP on cyclooxygenase 2 and prostaglandin E2 in 
mice with DSS-induced colitis. Protein expression of COX-2 (A) was 
determined by Western blotting while PGE2 (B) was determined by enzymatic 
immunoassay. The results from the six groups of mice (as described in 
Supplementary Figure 1) shown are representative of three independent 
experiments with 5 to 6 mice per group. *P<0.05, ***P<0.001 vs. CTL group; 
#P<0.05, ##P<0.01, ###P<0.001 vs. DSS group. 
Figure 5  Effects of DAPP on proinflammatory cytokines in mice with DSS-induced 
colitis. Gene and protein expression of the inflammatory markers TNF-a (A and 
D), IL-6 (B and E) and the transcription factors NF-kB (C and F) were 
determined by qPCR and Western blot respectively. The ratio NF-kB/IkB was 
then calculated. The results from the six groups of mice (as described in 
Supplementary Figure 1) shown are representative of three independent 
experiments with 5 to 6 mice per group. *P<0.05, **P<0.01, ***P<0.001 vs. 
CTL group; #P<0.05, ##P<0.01, ###P<0.001 vs. DSS group. 
Figure 6 Regulator effects of DAPP on peroxisome proliferator-coactivator-1 
(PGC1-α) and -activated receptor (PPAR) γ  in mice with DSS-induced 
colitis. The mitochondrial transcription and translation were evaluated by gene 
and protein expression of PCG1-α (A and B), PPAR-γ (C and D), determined 
by qPCR and Western blot respectively. The results from the six groups of mice 
(as described in Supplementary Figure 1) shown are representative of three 
independent experiments with 5 to 6 mice per group. *P<0.05, **P<0.01, 
***P<0.001 vs. CTL group; #P<0.05, ##P<0.01, ###P<0.001 vs. DSS group. 
Figure 7 Effects of DAPP on mitochondrial functions in mice with DSS-induced 
colitis. Mitochondrial ADP/ATP ratio (A) was measured by luciferase driven 
bioluminescence while the protein expression of AIF (B), Cyt C (C) and OGG1 
(D) in mitochondria was determined by Western blot. The results from four 
groups of mice (as described in Supplementary Figure 1) shown are 
representative of three independent experiments with 5 to 6 mice per group. 
**P<0.01, ***P<0.001 vs. CTL group; #P<0.05, ##P<0.01 vs. DSS group. 
Figure 8 Comparative analysis of functional enriched pathways between preventive 
and therapeutic DAPP treatments. The negative logarithm of p-values 
(Fisher's test), calculated by IPA, for each of the most significant 25 functional 
categories overrepresented in DSS/DAPP-400 was plotted against those 
modulated in DAPP-200/DSS. Insert: Venn diagram showing the 155 
canonical pathways between DSS/DAPP-400 and DAPP-200/DSS. Thresholds 
(dotted lines) denote the p=0.05 [-Log (0.05) =1.3]. B) List of the most 
significant twenty-five functional categories for DSS/DAPP-400 and DAPP-
200/DSS represented in A with their corresponding genes. 
Figure 9 Principal Coordinates Analysis (PCoA) plot and Heatmap of bacterial 
distribution of different communities. Figure 9A depicts the PCoA plot 
illustrating the clustering of sampled gut mucosal communities at the genus 






Samples are plotted as colored points and bacterial families or genera of 
interest as black vectors. This analysis was based on Bray-Curtis similarities of 
the log-transformed OTU abundances. Randomization test (999 permutations) 
indicates that the first two PCO axes are significant. The percent of variation 
explained for each axis is given in brackets. OTU, operational taxonomic unit. 
* Family group with unclassified genus. Figure 9B shows the Heatmap of the 
relative abundance (%) of selected bacterial taxa that were found in the control 
(CTL) and treated animal metagenomic samples (DSS, DSS+DAPP, 
DAPP+DSS). Each row corresponds to a family or genus of interest and each 
column to a mucosal metagenomics sample. The color scale represents the 
sample affiliation to its respective treatment, while the gray scale represents the 
abundance level (%). * Family group with unclassified genus. 
Figure 10 Pairwise mean proportional differences (%) calculated at the genus level 
between the control (CTL) and the treated animal metagenomic samples 
(DSS, DSS+DAPP, DAPP+DSS). The bar graphs on the left side display the 
mean proportion of sequences assigned to each selected family or genus. The 
dot plots on the right side show the bacterial genera that were overrepresented 
in one sample or another. Whiskers denote calculated 95% CIs. Only features 
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Scope: Inflammatory bowel diseases (IBD) are multifaceted and relapsing immune disorders, 
which necessitate long-term dependence on powerful drugs. As the use of natural product-
based therapies has emerged as a promising intervention, the present study aimed to further 
characterize dried apple peel powder (DAPP) mechanisms of action, and evaluate the 
preventive and curative effects of DAPP on mitochondrial functions in a murine model. 
Methods: Induction of intestinal inflammation in mice is performed by oral administration of 
the DSS at 2.5% for 10 days. Doses of DAPP (200 or 400 mg/kg/day) were administered by 
gavage for 10 days pre- and during-DSS. Results: DAPP limited DSS-induced histological 
lesions, improved macroscopic parameters and attenuated clinical signs. Concomitant with the 
reduction of massive infiltration of inflammatory cells, DAPP displayed a robust potential of 
counteracting inflammation and oxidative stress in DSS mice. Moreover, DAPP partially 
restored mitochondrial abnormalities related to size, density, redox homeostasis, fatty acid β-
oxidation, ATP synthesis, apoptosis and regulatory mitochondrial transcription factors. 
Conclusions: Our findings demonstrate the preventive and therapeutic impact of DAPP on 
experimental colitis while underlying the role of mitochondria. They also suggest that this 
natural DAPP product may represent an interesting candidate for further studies on the 














Inflammatory bowel diseases (IBD) are a group of chronic polygenic and debilitating immune-
mediated conditions with idiopathic Crohn’s disease and ulcerative colitis (UC) as the two 
main forms. The etiology of these recurring and incurable disorders remains obscure although 
the latter are generally considered to result from complex interactions between genetic 
determinants, unfavorable environmental factors and dysregulated gut microflora [1, 2]. 
Consequently, the loss of tolerance characterizing the intestinal immune system towards the 
microbiota leads to continual immune activation, mucosal damage and uncontrolled long-
lasting inflammation. The dramatically growing prevalence of IBD, absence of a cure, severe 
drug side effects, unresponsiveness to medical treatments and socio-economic burden pose 
special challenges for the scientific and medical community [3-5].	
Reactive oxygen species (ROS) play an important role in IBD. They are released in large 
amounts from phagocytic cells isolated from the inflamed bowels of patients with IBD in 
response to various stimuli [6-8]. ROS disturb intestinal homeostasis by causing DNA 
modifications and damage as noted by the significantly increased concentration of 8-
hydroxyguanine (8-OHdG) in the inflamed part of the bowel of Crohn’s patients [9]. The 
cellular imbalance between the reduced antioxidant levels and elevated ROS concentrations 
results in enhanced oxidative stress (OxS) [10-12]. The implication of OxS in IBD 
pathogenesis has been evidenced particularly by the attenuation of mucosal inflammation in 
response to CuZnSOD in Crohn’s patients [13] or by the beneficial effects of the antioxidant 






understanding of the mechanisms responsible for OxS is crucial for the development of 
effective prevention strategies and adequate intervention tools in IBD.	
Mitochondria are the primary cellular sources and sensitive targets of ROS [15]. It is quite 
understandable to detect mitochondrial dysfunctions in patients with IBD. Inflated ROS may 
damage mitochondrial proteins, lipids and DNA, thereby resulting in abnormal respiration and 
mitochondrial dysfunction, culminating in IBD expansion [16-18]. Accordingly, high 
mitochondrial lipid peroxidation along with deficient bioenergetics have been detected in the 
colonic epithelial cells of patients with UC [19]. Ultrastructural examination of the colonic 
mucosa in UC has shown the presence of abnormal mitochondria while biochemical analyses 
have revealed decreased activity of mitochondrial Complex II and acetoacetyl CoA thiolase 
(the enzyme catalyzing the final step in butyrate oxidation) in both the inflamed and non-
inflamed mucosa of patients with UC. Therefore it has been proposed that mitochondrial 
derangements are likely a primary defect to mucosal damage [19-21]. In line with these 
observations, genetic deletion of peroxisome proliferator-activated receptor-γ coactivator 1-α 
(PGC1α), the primary regulator of mitochondrial biogenesis, renders mice more susceptible to 
dextran sodium sulfate (DSS) colitis [22]. Altogether, most of these data indicate that 
dysregulation of OxS and mitochondrial dysfunction contributes to mucosal inflammation. 	
Polyphenols are natural compounds in plants, vegetables, fruits, olive oil, and wine. They 
captivate the attention and interest of scientists in view of their numerous biological properties 
including antioxidant, anti-inflammatory, antineoplastic, antiaging and antimicrobial activities 
[23]. Therefore, polyphenolic compounds have the robust potential to prevent or lessen the 
risks of diseases and the onset of disease progression by modulating several biological 






disease activity index, mucosal ulcerations, immune cell infiltration, lipid peroxidation and 
colonic inflammatory markers [25]. Our findings evidenced a significant improvement of all 
these harmful features in response to polyphenols contained in dried apple peel extract 
(DAPP). The present study aims at extending our understanding on the pathways controlling 
OxS and inflammation in experimental colitis by focusing especially on the implication of the 









Male C57BL6 mice (aged 6 weeks, weighing 17-20 gr) were purchased from Charles River 
(Montreal). They were housed in individual cages at 24 ± 1oC and exposed to a 12-h light/dark 
cycle with free access to tap water and to a standard laboratory chow diet (2018 Teklad 
Global, containing 18.6% protein, 3.5% carbohydrates and 6.2 % fat for 3.1 kcal/g, Harlan 
Laboratories, Indianapolis, IN) for 20 days. Experiments were performed during the light 
phase of the cycle. Animal experiments were conducted according to the Canadian Council on 
Animal Care guidelines for the care and use of experimental animals and were approved by 
the Institutional Animal Care Committee of the Sainte-Justine UHC Research Center.	
Induction of colitis and administration of DAPP	
After a one-week acclimation to their environment, mice were randomly allocated to six 
groups: (1) control mice (CTL) without colitis treated with water (as a vehicle) by oral gavage; 
(2) mice receiving DSS only (DSS mice) and administered the vehicle throughout the 
experimental period; (3) DSS mice receiving 200 mg/kg/day DAPP as a preventive treatment 
(DAPP-200/DSS); (4) DSS mice receiving 400 mg/kg/day DAPP as a preventive treatment 
(DAPP-400/DSS); (5) DSS mice receiving 200 mg/kg/day DAPP as a therapeutic treatment 
(DSS/DAPP-200); and (6) DSS mice receiving 400 mg/kg/day DAPP as a therapeutic 
treatment (DSS/DAPP-400) as well described in our previous paper [25].	
Colitis was induced by adding 3% (w/v) DSS (average molecular weight 36 000-50 000, MP 
Biomedicals) in the drinking water for 10 days. The preventive group received DAPP 10 days 






induction. DAPP (AppleActiv™, Leahy Orchards Inc.) was prepared as previously reported 
[25]. Body weight and food/water intake were measured on a daily basis. 	
Macroscopic and histological analysis of the colon	
In all mice, weight, presence of bloody stool, gross stool consistency and disease activity 
index were determined as previously described [25].	
Western blot analysis	
Homogenate, mitochondrial and nuclear protein extracts from colonic tissues were 
electroblotted onto Hybond nitrocellulose membranes following separation on a 7.5 % SDS-
PAGE. The immunoblot was incubated with blocking solution (defatted milk proteins) at 
room temperature and incubated overnight with a primary antibody. Blots were washed and 
incubated with a species-specific horseradish peroxidase-conjugated secondary antibody. 
Molecular size markers were simultaneously loaded on gels along with the β-actin protein to 
confirm equal loading. Blots were developed and the protein mass was quantified by 
densitometry using an HP Scanjet scanner equipped with a transparency adapter and the UN-
SCAN-IT gel 6.1 software as previously reported [26, 27].	
OxS and antioxidant defense	
Estimation of lipid peroxidation was assessed by malondialdehyde (MDA) using a 
fluorescence detector HPLC as described previously [28]. The quantification of hydrogen 
peroxide (H2O2) levels was determined using the fluorimetric hydrogen peroxide assay kit 








Samples of colonic mucosa were homogenized, centrifuged and their content of tumor 
necrosis factor (TNF)-α, inducible oxide synthase (iNOS) and cyclooxygenase-2 (COX2) 
proteins in the supernatant was measured by Western blotting as previously described [25].	
Isolation of mitochondrial organelles and functional studies	
The mitochondrial fraction was isolated from colonic samples by differential centrifugation 
according to our previously reported method [25, 30]. Briefly, after homogenization in sucrose 
extraction buffer (0,25M, pH 7,38) and light centrifugation (1000 g x 10 min at 4oC), the 
supernatant was ultracentrifuged twice (10000 g x 10 min at 4oC) to pellet mitochondria. Total 
mitochondrial proteins were quantified using the Bradford assay. ATP content was determined 
using the ATP bioluminescent assay kit from BioAssay Systems (Hayward, CA, USA) [30, 
31]. Apoptosis was evaluated by analyzing the protein expression of antiapoptotic Bcl2 and 
proapototic Bax, Cytochrome C (Cyt C) and apoptosis-inducing factor (AIF) by Western 
blotting. Mitochondrial antioxidant defense was assessed by measuring the protein expression 
of superoxide dismutase 2 (SOD2) and the major DNA glycosylase, 8-oxoguanine glycosylase 
(OGG1 that is responsible for removing the most abundant form of oxidative DNA damage) 
by Western blotting. The mitochondrial biogenesis master regulator peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) and its downstream transcription 
nuclear erythroid-2-p45-related factor-2 (NRF-2), as well as nuclear factor- kappa B (NF-kB) 
and activator protein-1 (AP-1) were also assessed by Western blot. Finally, β-oxidation, the 
major mitochondrial pathway for fatty acid (FA) degradation, was assessed by suspending 
colonic samples with U-C14 palmitic acid solution at 37o and evaluating 14CO2 and [14C]-acid-
soluble metabolites (ASM) at the end of a 2 h-incubation period in the presence of hydroxid 






expression of the enzymes carnitine palmitoyltransferase 1 (CPT1, that controls mitochondrial 
β-oxidation) and long chain acyl-CoA dehydrogenase (LCAD, that catalyzes the initial step of 
long FA β-oxidation) by Western blotting.	
Mitochondrial density and morphology 	
After removal of the colon, fresh tissue samples were immediately fixed in a 2% 
glutaraldehyde solution in 0.1 M cacodylate buffer (pH 7.4), post fixed in 1% osmium 
tetroxide in 0.1 M cacodylate buffer, dehydrated in increasing concentrations of ethanol and 
propylene oxide, and embedded in Epon. One-µm-thick sections were stained with toluidine 
blue to verify the orientation prior the ultrathin sectioning. Ultrathin sections were cut using an 
Ultracut S ultramicrotome (Leica) and mounted on nickel carbon-formvar coated grids. Uranyl 
acetate and lead citrate stained sections were imaged using a Philips CM100 electron 
microscope (FEI). Digital micrographs were captured using an AMT XR80 CCD digital 
camera at x34000 magnification. As described previously [33], individual mitochondria were 
manually traced using in ImageJ (NIH) to quantify the following morphological and shape 
descriptors: area (µm2), perimeter (µm), circularity (4π·(surface area/perimeter2)), Feret's 
diameter, longest distance (µm) between any two points within a given mitochondrion, aspect 
ratio (major axis)/(minor axis); a measure of the “length to width ratio” and form factor 
(perimeter)/(4π·surface area); a measure sensitive to the complexity and branching aspect of 
mitochondria.	
Statistical analysis	
All values are expressed as mean ± SEM.  Unless otherwise specified in the legends of the 






Prism 5.01 (GraphPad Software) and differences between means were assessed post-hoc using 







DAPP Reduces DSS-Induced Damage 	
Mice with DSS-induced colitis are one of the most commonly used animal models of IBD, 
however validation was necessary before evaluating the impact of preventive and therapeutic 
DAPP. Therefore, as illustrated in Fig. 1, symptomatic and histopathological features, similar 
to those seen in human UC, were obtained up to 10 days following DSS administration. 
Monitoring body weight loss, fecal bleeding, stool consistency and colon shortening in DSS-
induced colitis revealed a significant attenuation in response to DAPP treatment. In line with 
these macroscopic symptom findings, DAPP improved inflammation-associated histological 
changes triggered by DSS. This was noted by the reduction of lymphocyte infiltration, 
mucosal erosion, crypt damages and ulcer formation. Altogether, these observations highlight 
the preventive and therapeutic efficacy of DAPP in ameliorating colonic mucosal injury as 
evidenced by macroscopic and histopathological examinations (Fig. 2).	
DAPP decreases the expression of pro-inflammatory factors	
Because significant piling of inflammatory cells was seen in histological preparations of DSS-
treated animals, we assessed the protein expression of pro-inflammatory biomarkers such as 
TNF-α, COX-2 (involved in arachidonic acid metabolism) and iNOS (catalyzing NO 
formation). Indeed, per os treatment of mice with DSS enhanced the protein expression of all 
these pro-inflammatory proteins relative to untreated mice, whereas DAPP administration 
significantly reduced these increased levels (Fig. 3). Therefore, DAPP are compounds with 
potential anti-inflammatory properties in adverse situations such as inflammation-associated 
colitis.	






The implication of OxS in the complex IBD pathophysiology is widely accepted; therefore, its 
occurrence was assessed by determining MDA levels in the mouse groups. HPLC analysis 
showed a significant elevation of MDA in the distal colon of DSS-treated mice compared with 
that of the healthy control mice (Fig. 4A). Nevertheless, its magnitude was restrained by the 
preventive 200 mg/kg/day and the therapeutic 400 mg/kg/day doses of DAPP, likely through 
the beneficial alterations in the endogenous antioxidant GPx-1 (Fig. 4B). Then, we determined 
the protein expression of NRF-2 transcription factor since this is one of the critical regulators 
of intracellular redox homeostasis. In fact, disruption of NRF-2 protein expression by DSS 
was prevented or mitigated by DAPP. Thus, DAPP alleviated NRF-2 abrogation, which raised 
antioxidant defense mechanisms, thereby contributing to the reduction in DSS-induced (Fig. 
4C).	
DAPP interferes with the mitochondrial formation of OxS	
As mitochondria are considered the main quantitative source of OxS, we measured the 
influence of DSS and DAPP on the mitochondrial H2O2 content in the different mouse groups. 
Intra-mitochondrial H2O2 metabolite and SOD2 protein expression were elevated in the DSS 
exposed group compared to the control mice (Fig. 5). Moreover, DSS mice having undergone 
preventive or therapeutic DAPP gavage exhibited a marked reduction in H2O2 and SOD2 
protein expression. The focus was also placed on 8-oxoguanine DNA glycosylase 1 (OGG1), 
the most important enzyme involved in DNA repair via the removal of 8-oxoguanine elicited 
by OxS. While DSS altered OGG1, DAPP upregulated its expression. Therefore, DAPP 
administration slowed down mitochondrial OxS in DSS-induced colitis.	






As the pivotal role of mitochondria in the execution of cell death is well established, apoptosis 
was assessed by estimating the protein expression of anti-apoptotic Bcl2 and the pro-apoptotic 
Bax, Cyt C and AIF transcription factor. While DSS treatment resulted in significantly 
decreased Bcl2 and increased Bax, as well as Cyt C and AIF transcription factor, DAPP 
displayed the capacity to limit apoptosis (Fig. 6).	
DAPP modulates FA β-oxidation	
One of the most important functions of the mitochondria is the β-oxidation of FAs to maintain 
body energy homeostasis. Accordingly, as illustrated in Fig. 7, the degradation of [14C]-
palmitate to [14C]-CO2 and acid-soluble metabolites (ASM) was significantly affected 
following DSS treatment. However, the preventive and therapeutic DAPP supplementation 
resulted in a less dramatic decline of [14C]-palmitate conversion into CO2 and acid-soluble 
metabolites, indicating enhanced total β-oxidation in DSS-induced colitis. We reasoned that 
the expression of key mitochondrial regulatory enzymes such as carnitine 
palmitoyltransferase-1 (CPT-1) and ACADL should present the same trend.  Consistent with 
the findings of [14C]-palmitate β-oxidation to CO2 and ASM, a low protein expression of CPT-
1 and ACADL was observed in the DSS-treated mice, whereas DAPP narrowed their down-
regulation (Fig. 8A-8B). Overall, our data underline the ability of DAPP to positively 
modulate the β-oxidation.	
DAPP enhances the mitochondrial energetic competence to produce ATP	
The production of ATP molecules is instrumental in energy homeostasis. We therefore 
evaluated changes in mitochondrial ATP concentrations in the distal colon. Decreased levels 
were detected in mice with DSS-induced colitis compared to control mice, but DAPP 






DAPP is able to induce an increase in PGC1α and PPAR γ protein expression in DSS-
induced colitis	
To further understand the mechanisms behind the modulatory role of DAPP, the protein 
expression of PGC-1α was measured. This transcription factor regulates mitochondrial 
biogenesis as well as protein composition and function. The data in Fig. 9 indicates the decline 
of PGC-1α in mice with DSS-induced colitis compared with control mice. However, 
improvement was noted with DAPP supplementation. Since PGC1a acts as a transcriptional 
co-activator of nuclear receptors and other transcription factors regulating mitochondrial 
biogenesis, we analyzed the expression of PPARγ that plays an important role in maintaining 
the intestinal immune balance and may exert anti-inflammatory effects in UC [34, 35]. The 
same phenomenon was observed in the other transcription factors NF-kB and AP-1 (Fig. 10).	
DAPP attenuates DSS-induced alteration in mitochondrial morphology	
It is now widely accepted that changes in mitochondrial morphology can greatly impact 
mitochondrial function and vice versa. Considering the protective effects of DAPP against 
DSS-induced mitochondrial dysfunction, we investigated whether DSS and DAPP treatments 
altered mitochondrial morphology on TEM images. As can be seen in Fig. 11, DSS-induced 
colitis decreased mitochondrial density. Interestingly, our data suggest that DAPP 
supplementation partially protected from this DSS-induced reduction in mitochondrial content 
since no differences between control and DAPP treated animals were observed. Although no 
effect of DSS on mitochondrial area was observed, mitochondria from DSS-treated mice 
displayed changes in multiple indicators of mitochondrial morphology, which is compatible 
with a reduction in mitochondrial complexity and an increase in mitochondrial fragmentation 






Interestingly, DAPP supplementation protected from DSS-induced alteration in mitochondrial 
morphology. The increase in mitochondrial area and perimeter seen in the preventive DAPP 









Mitochondria regulate vital functions necessary in maintaining overall cellular homeostasis. 
Despite the role of mitochondria in OxS, energetics, apoptosis, epithelial junction integrity and 
innate immune response, all known to be implicated in IBD, only limited information is 
available on the link between mitochondrial biological behavior and IBD pathogenesis. In 
addition, the impact of key bioactive polyphenols in the management of IBD and especially on 
mitochondrial functions has not been fully explored. This represents an important task since 
many current pharmacological drugs are not fully satisfactory, and the development of more 
effective therapeutic agents is greatly needed. To reinforce and deepen knowledge on the role 
of DAPP in intestinal inflammation, we chose the DSS-induced murine colitis that closely 
mimics the changes observed in the colonic epithelium of UC patients. Following validation of 
the DSS model, our experiments evidenced the beneficial and protective influence of DAPP 
while providing an insight and underlying some of the mechanisms responsible for the 
preventive and therapeutic actions of these functional foods. In particular, our findings stress 
the attenuation of DSS-induced mitochondrial dysfunction by DAPP. 	
As Bcl2 family proteins have emerged as critical regulators of mitochondria-mediated 
apoptosis by functioning as either a promoter (e.g. Bax) or an inhibitor (e.g. Bcl2) of the cell 
death process [36, 37], we evaluated the expression of Bax and Bcl2. The inflammatory 
condition caused by the DSS chemical agent was accompanied by an increase in the 
expression of pro-apototic Bax along with a decrease in anti-apoptotic Bcl2 within the 
mitochondria. This resulted in an increase in the ratio of Bax/Bcl2, which could elicit the 
apoptotic process. We confirmed the exaggerated apoptosis by examining the protein 






space between the mitochondrial inner and outer membranes [38] and released into the 
cytoplasm to enhance the intrinsic apoptosis signaling pathways [39]. Concomitantly with the 
high Bax/Bcl2 ratio, the levels of Cyt C and AIF were raised significantly. Collectively, our 
observations clearly indicate a DSS-induced cell death program, mechanistically mediated by 
mitochondrial pathways. To further identify the bioactivity of DAPP, we analyzed its ability to 
prevent or inhibit this mitochondria-dependent apoptotic pathway. We found that treatment of 
DSS-induced colitis mice with DAPP led to a consistent rise of anti-apoptotic Bcl2 and 
decline in pro-apototic Bax, Bax/Bcl2 ratio, Cyt C and AIF. Overall, our data support that 
DAPP constitutes an effective functional nutrient that could prevent and treat mitochondrial 
dysfunction caused by DSS. However, additional efforts are certainly needed to clarify the 
underlying mechanisms. For now we may suggest that the presence of DAPP retains Bcl2 in 
the cytosol, complexed with Bax, thereby avoiding apoptosis by impeding Bax translocation to 
the mitochondria. Without DAPP, Bax may form a channel for the exit of Cyt C and AIF with 
a concomitant opening of mitochondrial permeability transition pore (MPTP) and a collapse of 
mitochondrial membrane potential [40, 41]. Importantly, inhibition of MPTP opening has been 
identified as a promising therapeutic target in preventing cell damage [42]. 
Lipid metabolism largely depends on mitochondria to generate cellular energy. We argued that 
if DSS-induced colitis affects mitochondrial dysfunction, FA β-oxidation would be affected. 
To test this hypothesis, colonic tissue specimens were incubated with [U-14C]-palmitate. There 
was a significant reduction in 14C–palmitate–derived CO2 and ASM release from the intestinal 
explants of DSS-induced colitis. Accordingly, butyrate metabolism was reported to be 
defective in the colonic mucosa of UC patients and an animal model of colitis [43-45]. 






DSS-induced colitis mice led to an enhanced production of 14CO2 and ASM. One potential 
explanation for the dysfunction of mitochondrial FA oxidation in response to DSS may lie in 
the faulty expression of CPT1a (a rate-limiting enzyme located on the mitochondrial outer 
membrane and controlling mitochondrial entry of long chain FA) and/or ACADL (a key 
enzyme participating in FA oxidation). As anticipated, the mass of the two enzymes was 
markedly decreased in mice with DSS-induced colitis, an effect highly counteracted by DAPP 
supplementation. Similarly, DAPP partially restored colonic ATP decline mediated by DSS 
administration. These results show that the polyphenol-rich extract enhances mitochondrial 
FA import and oxidation. This suggests that DAPP can be regarded as a robust functional food 
capable of ameliorating intestinal inflammation most likely through facilitating mitochondrial 
FA β-oxidation and promoting energy production. 
PGC-1α acts as a central regulator of mitochondrial biogenesis and energy metabolism [46, 
47]. It exhibits the potential to bind to various downstream transcriptional nuclear respiratory 
factors such as PPARγ, NRF-2 and mitochondrial DNA transcription factor A (mtTFA), to 
regulate mitochondrial proliferation and function [48, 49]. This master co-transcriptional 
regulation factor also controls ROS metabolism by activating NRF-2 and triggering 
antioxidant factors, thereby disclosing high effectiveness in inducing mitochondrial 
antioxidant expression [50]. To provide just a few examples, PGC-1α mediated the 
upregulation of mitochondrial antioxidant enzyme activity in cultured vascular endothelial 
cells [51], as well as in brain [50] and heart [52] tissues. A significant drop of PGC-1α was 
recorded in mice with DSS-induced colitis, which explains diverse mitochondrial dysfunctions 
related to mitochondrial density, respiration, ATP generation and pro-oxidant/antioxidant 






expression in these mice, in response to DAPP, might have contributed to the greater 
antioxidant defense, but studies are required to determine the distinct contribution of PGC1α 
and PGC1α-dependent Nrf2 expression. Additionally, PGC1α may act through its downstream 
target PPARγ, whose elevation in response to DAPP supplementation may produce the 
observed beneficial mitochondrial actions [53]. Finally, it is important to mention that PGC1α-
mediated mtTFA, which was found stimulated by polyphenols in our previous studies [31], 
may have contributed to the improved functions associated with DAPP supplementation. 
Mitochondrial DNA (mtDNA) damage resulting from increased OxS is emerging as an 
important factor in the pathogenesis of various disorders. A prevalent lesion that occurs in 
mtDNA damage is the formation of 8- hydroxy-2’-deoxyguanosine (8-OHdG), which can 
cause mutations and mitochondrial dysfunction, while triggering apoptotic cell death if not 
repaired properly by 8- oxoguanine DNA glycosylase (OGG1) [54]. Here, we report that the 
colonic tissues of DSS-induced colitis mice have decreased OGG1 protein levels. This was 
associated with the increased levels of 8-OHdG noted in our previous studies [30]. Exposure 
to DAPP resulted in a partial correction of OGG1 in agreement with the diminished 8-OHdG. 
We therefore conclude that DAPP-dependent antioxidant strengthening influenced mtDNA 
repair process; thereby preventing oxidant-mediated mitochondrial dysfunction and apoptotic 
cell death.  
Once exclusively considered as bean-shaped structures, mitochondria are now recognized as 
dynamic organelles capable of changing their morphology through fusion and fission 
processes while harbouring complex morphology, e.g. elongated and branched structures. It is 
also now widely established that mitochondrial morphology and function are intertwined, with 






mitochondrial fusion and the concomitant increase in complexity are frequently associated 
with improved mitochondrial function [55]. Here, we report that DSS treatment, in addition to 
reducing mitochondrial density, is associated with a mitochondrial fragmentation in 
combination with a reduction in mitochondrial complexity (increased in circularity, decreased 
in aspect ratio and form factor values). This decrease in mitochondrial complexity is in line 
with the DSS-induced mitochondrial dysfunction we report herein. Importantly, DAPP 
treatment completely abolished the effects of DSS on mitochondrial morphology. Therefore, 
our results suggest that impairment of mitochondrial dynamics (fusion and fission processes) 
in enterocytes might be involved in the etiology of DSS-induced colitis. They also suggest that 
DAPP might positively influence mitochondrial dynamics. Further studies are now required to 
assess the potential role of impaired mitochondrial dynamics in IBD.	
In conclusion, our preclinical studies have emphasized the positive effects of DAPP on 
ameliorating the severity of DSS-induced colitis via the reduction of OxS and inflammation. 
In particular, we showed that DAPP may influence mitochondrial functions in colonic cells, 
including pro-oxidant/antioxidant balance, β-oxidation, cell death, and ATP production, which 
are all fundamental processes critical for the maintenance of cell homeostasis and integrity. As 
DAPP markedly decreased chemically induced colitis through these specific mechanisms 
implicated in IBD, they may be highly effective in protecting against the chronic inflammation 
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Figures 1&2 Effects of DAPP on DSS-induced colitis. The disease activity index, scores 
for the body weight change, stool consistency, fecal bleeding, and the 
microscopic damage determined the severity of the colitis. Colon sections were 
scored for DSS‐induced colonic inflammation and tissue injury as described in 
Materials and Methods.	
The body weight change was determined by calculating the percentage of 
weight change relative to the starting weight before DSS treatment (0 = none; 1 
= 1-5%; 2 = 5-10%; 3 = 10-20% and 4 = >20%). The fecal condition score was 
determined using two parameters: stool consistency (0 = normal; 1 = 
moist/sticky stool; 2 = soft stool; 3 = soft stool with mild diarrhea; 4 = diarrhea 
only) and fecal bleeding (0 = no blood; 1 = minimal blood in stool; 2 = mild 
blood in stool; 3 = evidence blood in stool and 4 = only blood). The pictures 
were taken using a digital camera at 20X resolution. The results shown are 
representative of three independent experiments with n=8 mice/group. 
**P<0.01 vs. CTL group; #P<0.05, ##P<0.01 vs. DSS group. 	
Figure 3 Effects of DAPP on proinflammatory cytokines in mice with DSS-induced 
colitis. Protein expression of the inflammatory markers was determined by 
Western blot as described in Materials and Methods. The results shown are 
representative of three independent experiments with n=8 mice/group. 
**P<0.01 vs. CTL group; #P<0.05, ##P<0.01 vs. DSS group.	
Figure 4 Effects of DAPP on oxidative stress markers in mice with DSS-induced 






malondialdehyde (MDA) by HPLC (A). The protein expression of glutathione 
peroxidase (GPx) (B) and the transcription factor Nrf2 (C) were determined by 
Western blot as described in Materials and Methods. The results shown are 
representative of three independent experiments with n=8 mice/group. 
**P<0.01 vs. CTL group; #P<0.05, ##P<0.01 vs. DSS group.	
Figure 5 Effects of DAPP on mitochondrial oxidative stress in mice with DSS-
induced colitis. 	
                       Intra-mitochondrial H2O2 metabolite (A) was determined by using the 
fluorimetric hydrogen peroxide assay kit. The protein expression of superoxide 
dismutase (SOD2) (B) and 8-oxoguanine DNA glycosylase 1 (OGG1) (C) were 
determined by Western blot as described in Materials and Methods. The results 
shown are representative of three independent experiments with n=8 
mice/group. *P<0.05, **P<0.01 vs. CTL group; #P<0.05, ##P<0.01 vs. DSS 
group.	
Figure 6 Effects of DAPP on mitochondrial apoptosis in mice with DSS-induced 
colitis. 	
Protein expression of anti-apoptotic Bcl2 (A) and the pro-apoptotic Bax (B), 
Cyt C (D) and AIF transcription factor (E) were verified by Western blot as 
described in Materials and Methods. Moreover, the Bax/Bcl2 ratio was 
calculated (C). The results shown are representative of three independent 
experiments with n=8 mice/group. *P<0.05, **P<0.01 vs. CTL group; #P<0.05, 






Figure 7 Effects of DAPP on mitochondrial fatty acid oxidation in mice with DSS-
induced colitis. 	
                        Mitochondrial pathway for fatty acid (FA) degradation was determined by 
suspending colonic tissues with U-14C palmitic acid solution and by calculating 
14CO2 (A) and [14C]-acid-soluble metabolites (ASM) (B) as described in 
Materials and Methods. The results shown are representative of three 
independent experiments with n=8 mice/group. *P<0.05, **P<0.01 vs. CTL 
group; #P<0.05 vs. DSS group.	
Figure 8 Impact of DAPP on the expression of two main mitochondrial enzymes in 
mice with DSS-induced colitis. 	
                       The expression of the enzymes carnitine palmitoyl transferase 1 (CPT1) (A) and 
long chain acyl-CoA dehydrogenase (LCADL) (B) were analyzed by Western 
blot as described in Materials and Methods. Also, mitochondrial ATP 
generation (C) was measured using the ATP bioluminescent assay kit. The 
results shown are representative of three independent experiments with n=8 
mice/group. **P<0.01 vs. CTL group; #P<0.05, ##P<0.01 vs. DSS group. 	
Figure 9 Regulatory effects of DAPP on peroxisome proliferator-coactivator-1 
(PGC1-α) and -activated receptor (PPAR) γ in mice with DSS-induced 
colitis. 	
The expression of transcription factor peroxisome proliferator-coactivator-1 
(PGC1-α) (A) and -activated receptor (PPAR)γ (B) were illustrated by Western 






representative of three independent experiments with n=8 mice/group. 
**P<0.01 vs. CTL group; #P<0.05, ##P<0.01 vs. DSS group.	
Figure 10 Effects of DAPP on nuclear factor- kappa B (NF-kB) and activator 
protein-1 (AP-1) in mice with DSS-induced colitis. 	
                        Protein expression of the transcription factor NF-kB (A) and pro-inflammatory 
factor AP-1 (B) were measured by Western blot as described in Materials and 
Methods. The results shown are representative of three independent 
experiments with n=8 mice/group. **P<0.01 vs. CTL group; #P<0.05, ##P<0.01 
vs. DSS group.	
Figure 11 Effects of DAPP on mitochondrial morphological structure and density. 
Representative TEM images of enterocytes from control and DSS-treated mice 
(A), as well as from mice treated with DAPP before (DAPP-200/DSS) or after 
(DSS/DAPP-400) treatment. These images were used for the quantification of 
mitochondrial volume density and parameters related to mitochondrial 
mitochondrial morphology (B). For each group, mitochondrial density was 
quantified using multiple images collected from 2 different animals. 
Mitochondrial area (C), perimeter (D), circularity (E), roundness (F), form 
factor (G) and aspect ratio (H) were obtained by manually tracing mitochondria 
on TEM images obtained from 2 different mice per group (control: n=95; DSS: 
n=53; DAPP-200/DSS: n=72; DSS/DAPP-400: n=71). The graph in J 
represents, for each group, the percentage of mitochondria with simple (i.e. 
mitochondria with aspect ratio and factors inferior to the 25th percentile of 






the 75th percentile of control values) and intermediate (i.e. neither simple nor 
complex). Due to the fact that data in (C-H) did not pass the D’Agostino & 
Pearson omnibus normality test, data in these graphs we analyzed by Kruskal-






















4   DISCUSSION  
The interaction between inflammation and oxidative stress is associated with the evidence of 
their concomitant manifestation in IBD [50]. IBD is a chronic inflammatory disease that 
causes significant health problems worldwide. Currently there is no definite cure available for 
IBD that can threaten patients’ life, affect their quality of life and impose great financial 
burden. In these conditions, many scientists and clinicians attempt to discover functional foods 
without secondary effects. 
In fact, the use of functional nutrients such as polyphenolic compounds as alternative 
medicines have been recognized by different scientific groups, but their function and 
mechanisms of action in the management of IBD and especially on mitochondrial functions 
have not been clearly studied. As mitochondria are highly important for the maintenance of 
homeostasis in all tissue cells, we examined their biological functions and responses to DAPP 
administration in experimental colitis. 
 The present studies have highlighted abnormal mitochondrial OxS and dysfunction in 
intestinal epithelium of mice with DSS-induced colitis, which mimics tissues from patients 
with gut inflammation (IBD) [116] or epithelial monolayers treated with powerful prooxidants 
[112]. Our aims were also to extend and unravel the role of DAPP in intestinal inflammation 
by focusing on mitochondria. 
Previous studies indicated that different polyphenols could inhibit OxS and inflammation 
pathways [170-172]. In this context, we chose DAPP, which is a rich source of polyphenols 
that revealed anti-inflammatory and antioxidant activities in our previous study [169]. In this 
context, it is noteworthy to note that other researchers proposed apple peels as a valuable 






polyphenols (200 and 400 mg/kg/day) were used in our experiments in order to evaluate how 
mice with DSS-induced experimental colitis react to physiological (200 mg/kg/day) and supra-
physiological (400 mg/kg/day) doses [175].  
Special attention was given in our investigation to the assessment of the regulatory DAPP 
effects on intestinal integrity and on the mechanisms of mitochondrial dysfunction in the DSS-
induced colitis model.  We first found that DAPP supplementation slowed body weight loss, 
diminished diarrhoea and prevented bloody stools at a macroscopic level. In addition, this 
treatment improved colon shortening and colonic histological damages at a microscopic level 
by reducing inflammatory cell invasion into colonic tissues. DAPP also decreased neutrophil 
infiltration in the colonic tissue as noted by the reduced colonic myeloperoxidase activity, 
which represents a valuable marker of inflammatory cell infiltration in DSS-induced colitis 
mice. 
Our results demonstrated that DSS animals were characterized by an overproduction of pro-
inflammatory cytokines such as TNF-α and IL-6, which are implicated in the pathogenesis of 
colitis [176, 177]. Accordingly, previous reports showed that the levels of these pro-
inflammatory cytokines are directly correlated to the severity of colitis [178, 179]. 
Interestingly, our studies clearly indicate that the influence of DAPP results in reduced 
inflammation by blocking the expression of pro-inflammatory cytokines (TNF-α and IL-6), 
which may prevent or stop the pathological progression of pro-inflammatory cascade such as 
NF-𝜅B signal transduction pathway.  Our results are clearly consistent with Li’s study by 
showing the capacity of DAPP treatment to moderate NF-𝜅B signals, while augmenting the 
expression of the inhibitory subunit IκB and then leading to the reduction of the NF-𝜅B /IκB 






Interestingly, the disruption in NF-κB modulation can change prostaglandin metabolism with 
an effect on inflammation and cancer occurrence in IBD [52]. Prostaglandins participate in 
inflammatory activities and damage the integrity of the colon. Also, in inflammatory 
conditions, proinflammatory cytokines cause the increased of COX-2, one of main forms of 
the COX enzymes. COX-2 is capable to transform arachidonic acid into prostaglandins [53]. 
Our findings reveal that DAPP treatment is significantly effective to facilitate the down-
regulation of COX-2, as a protein implicated in immune dysregulation in IBD [181], while 
limiting the production of PGE2, a main downstream agent of COX-2 and consequently 
ameliorating DSS-induced colitis. The down-regulation of the COX-2-PGE2 pathway by 
preventive and therapeutic DAPP supplementation can be of high interest for IBD. We also 
measured the expression of Bcl2 family proteins, as main regulators of mitochondria-mediated 
apoptosis, such as Bax, a promoter of the cell death process, and Bcl2, an inhibitor of the cell 
death process and their ratio of Bax/Bcl2 [182, 183]. In DSS-induced colitis, we observed that 
the inflammation raised pro-apototic Bax while it limited the production of anti-apoptotic Bcl-
2 in the mitochondria, thereby causing the rise in the ratio of Bax/Bcl2 and amplifying the 
process of apoptosis. To recognize the severity of apoptosis, we also measured the protein 
expression of Cyt C and AIF. Cyt C and AIF proteins are normally located in the space 
between the mitochondrial inner and outer membranes [184] but, in  inflamed conditions, they 
move into the cytoplasm to increase the principal apoptosis signaling pathways [185]. Our 
findings show the high levels of AIF and Cyt C protein expression in DSS-treated mice, 
concomitantly with the increased ratio of Bax/Bcl2. Remarkably, our findings confirm the 
effectiveness of DAPP in raising anti-apoptotic Bcl2 while provoking fall in pro-apoptotic 






to illuminate the underlying mechanisms. These results may suggest that DAPP can maintain 
Bcl2 in junction with Bax that are both normally located in the cytosol and thus it may prevent 
apoptosis pathway by inhibiting Bax to enter mitochondria. In the inflammation situation 
without DAPP, the binding of Bax to mitochondria may create a pathway for the release of 
Cyt C and AIF into the cytoplasm simutaneously with the opening of MPTP, which may 
decrease the mitochondrial membrane potential [186]. DAPP could be used as a therapeutic 
factor by prohibiting MPTP opening and thus controlling cell death [187]. 
Knowing that FA catabolism occurs in mitochondria to produce cellular energy, we wanted in 
the present study to determine whether β-oxidation would be affected as a result of the 
mitochondrial dysfunction observed in DSS-induced colitis. Therefore, we incubated colonic 
tissue with [U-14C]-palmitate to assess palmitate conversion to CO2 and ASM. We observed 
that in DSS-induced colitis mice, CO2 and ASM generation significantly declined. On the 
other hand, DAPP supplementation resulted in increased production of CO2 and ASM and 
thus improving total β-oxidation.  Decrease in FA catabolism was also demonstrated by other 
studies that showed significant reduction in butyrate oxidation in experimental colitis model 
and colonic mucosa of UC patients [122, 188]. The defective expression of two important 
enzymes such as carnitine palmitoyltransferase 1a, an enzyme residing on the mitochondrial 
outer membrane and regulating mitochondrial entry of long chain FA, and ACADL, a vital 
enzyme for FA β-oxidation, may be the reason for the dysfunction of mitochondrial FA β-
oxidation. Our data showed a significant lowering in the expression of both enzymes in DSS-
induced colitis mice, whereas the protective and therapeutic role of DAPP resulted in 






Our studies showed decreased mitochondrial ATP concentrations in colonic tissues of DSS-
induced colitis mice as well as a diminished level of the ratio of ADP/ATP, a key parameter in 
mitochondrial energy metabolism and respiration.  DAPP supplementation partially attenuated 
the decrease in ATP and ADP/ATP ratio. Therefore, the present results in experimental colitis 
confirm previous studies in which polyphenols can improve the loss of mitochondrial 
membrane potential, correct the increase in lipid peroxidation and the fall in cellular ATP 
induced by indomethacin in Caco-2 cells [189]. Consequently, one possible explanation for 
improving intestinal inflammation is probably via the stimulation of mitochondrial FA β-
oxidation and elevating ATP production pathways in DSS-induced colitis mice. 
PGC-1α plays a key role as a main modulator of mitochondrial biogenesis and a 
transcriptional regulator of cellular energy activities, including OXPHOS and FA oxidation 
[86, 190]. This principal transcription factor improves ROS metabolism by provoking the 
expression of Nrf-2 [191]. The activation of Nrf2 can then cause the production of endogenous 
protective antioxidative SOD and GPx enzymes, which could initiate the up-regulation of 
cytoprotective proteins and also the transcription of antioxidant genes [192]. In addition, PGC-
1α can bind to additional transcriptional nuclear factors, including PPARγ and mtTFA to 
control mitochondrial proliferation and function [191, 193]. Our results demonstrated a 
significant fall in PGC-1α level in mice with DSS-induced colitis with a concomitant 
reduction in the expression of Nrf2, which may have caused mitochondrial disorders relevant 
to pro-oxidant/antioxidant disequilibrium. However, the antioxidant effect of DAPP 
polyphenols was able to correct the mitochondrial status by upregulating the expression of 
PGC-1α and Nrf2 in DSS mice, which collectively improved the antioxidant defense by 






regulation of transcriptional nuclear factor PPARγ in experimental colitis, while DAPP 
preventive and therapeutic treatment restored its expression. It is likely that the action of 
DAPP on PGC-1α is related to the modifications of PPARγ. 
Increased level of OxS can result in mtDNA damage, which is an important factor in the 
pathogenesis of different disorders. The high production of 8-OHdG is one of the widespread 
injuries that happen when mtDNA is damaged. Conversely, OGG1 can correct the production 
of 8-OHdG. The rise of 8-OHdG, due to the lack of repair by OGG1, provokes mutations, 
mitochondrial dysfunction and finally initiates apoptotic cell death [132]. Our findings suggest 
that the expression of OGG1 protein in experimental colitis mice was decreased in correlation 
with augmented production of 8-OHdG. In contrast, DAPP showed the ability to counteract 
the DSS-induced fall of OGG1. Consequently, the powerful antioxidant properties of DAPP 
can affect the mtDNA repair pathways and may prevent mitochondrial dysfunction. 
Mitochondria are known to be vital organelles that can change their morphology via fusion 
and fission processes. Importantly, under normal conditions, mitochondrial function depends 
on fusion process of mitochondria. Since mitochondrial morphology and function are 
interconnected, any changes in mitochondrial morphology can seriously affect mitochondrial 
function. It is known that mitochondrial fragmentation is usually correlated with mitochondrial 
dysfunctions. In our second study we observed diminished mitochondrial density related to 
mitochondrial fragmentation and decreased mitochondrial complexity (increased circularity, 
decreased aspect ratio and form factor values) in DSS induced mice. However, DAPP 
treatment was able to completely correct the effects of DSS on mitochondrial morphology. 
Therefore, our results suggest that DAPP treatment has a potential to impact mitochondrial 







5   CONCLUSIONS  
These preclinical studies demonstrate the importance of mitochondria as a major source and 
target of oxidative stress. We showed that the intake of DAPP in an experimental colitis 
mouse model is beneficial in the preventive and therapeutic management of DSS-induced 
colitis. These beneficial effects of DAPP were achieved through the improvement of 
mitochondrial dysfunctions by decreasing OxS and inflammation. 
Our findings indicate that administration of DAPP could affect microbiota and mitochondrial 
functions (i.e. proxidant/antioxidant balance, ATP production, β-oxidation and cell death) in 
inflamed bowel cells, which represent vital functions and processes in the protection of cell 
homeostasis and integrity; finally leading to optimal health. 
In addition, these modifications lead to other improvements related to bleeding, stool 
consistency, histological aberrations, weight loss and colon shortening. This further reveals the 
powerful preventive and therapeutic effects of apple polyphenols in managing, treating and 
improving IBD. In conclusion, our findings show amelioration of chronic inflammation in 
mouse IBD, in particular, improvement of mitochondrial dysfunctions by specific antioxidant 
mechanisms triggered by DAPP. Future clinical research is needed to determine if DAPP 
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